

AWARD NUMBER: W81XWH-19-1-0689

TITLE: Risk of Hepatocellular Cancer After Virological Cure with Direct Acting Antiviral Agents in Individuals with Hepatitis C

PRINCIPAL INVESTIGATOR: Fasiha Kanwal, MD, MSHS

CONTRACTING ORGANIZATION: Baylor College of Medicine

REPORT DATE: OCTOBER 2022

TYPE OF REPORT: Annual Technical Report

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE OCTOBER 2022		2. REPORT TYPE Annual Technical Report		3. DATES COVERED 09/01/2021 - 08/31/2022	
4. TITLE AND SUBTITLE Risk of Hepatocellular Cancer After Virological Cure with Direct Acting Antiviral Agents in Individuals with Hepatitis C				5a. CONTRACT NUMBER W81XWH-19-1-0689	
				5b. GRANT NUMBER PR181562	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Fasiha Kanwal, MD, MSHS and Jagpreet Chhatwal, PhD Email: Kanwal@bcm.edu and jagchhatwal@mgh.harvard.edu				5d. PROJECT NUMBER 0011335790-0001	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Baylor College of Medicine One Baylor Plaza Houston, TX 77030-3411				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Purpose: The overarching goal of this project is to reduce HCC-related morbidity and mortality in persons with chronic hepatitis C (CHC) who have been virologically cured by direct acting antivirals (DAAs). Aims: 1) Examine determinants of HCC in virologically cured patients and develop a risk prediction model for HCC; 2) Conduct a virtual clinical trial using a mathematical model of the natural history of HCC to evaluate benefits vs harms of HCC surveillance; 3) Develop an online HCC Simulator. Design: Using cause-specific Cox proportional hazard models for competing risks, we will identify risk factors in a retrospective cohort study of >100,000 patients with DAA-induced SVR. For dynamic risk prediction of HCC, we will use the landmark Cox model. We will use a mathematical model to simulate a virtual trial comparing long-term effectiveness of no surveillance vs routine surveillance. Finally, we will develop an interactive decision support tool. Progress: The project is in final stages of completing the HCC Simulator on-line tool. Target completion date 09/30/2023. Findings: We identified a range of predictors for HCC in virologically cured patients with CHC. Risk factors for HCC were different in patients with and without cirrhosis and some also evolved during follow-up. These factors can help with risk stratification and HCC surveillance decisions in patients with cured HCV. These findings were reported in a manuscript accepted for publication in Am J Gastroenterology. The AUCs for the models in patients with and without cirrhosis were 0.72 (95% CI, 0.70-0.74) and 0.68 (95% CI, 0.66-0.70), respectively. A Mathematical model of the natural history of HCC in DAA-cured CHC patients was developed that led the team to conclude that the burden of HCC will shift from viremic to virologically cured CHC patients, and to older populations in the next decade. These findings are reported in a meeting abstract that will be presented during the Liver Meeting 2021 and a manuscript that was accepted by JAMA Network Open.					
15. SUBJECT TERMS: Hepatocellular carcinoma; Chronic hepatitis C (CHC); Direct-acting antivirals (DAAs); Sustained viral response (SVR); Risk stratification; Protective factors; Risk factors; Risk prediction models; Benefits and harms; Decision support tool; Simulator tool; Cancer surveillance					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRDC
Unclassified	Unclassified	Unclassified	Unclassified	55	19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4-12
4. Impact	12
5. Changes/Problems	12
6. Products	13
7. Participants & Other Collaborating Organizations	14-43
8. Special Reporting Requirements	43
9. Appendices	44-55

1.INTRODUCTION: Hepatocellular carcinoma (HCC) is the fastest growing cause of cancer deaths in Americans. HCC incidence has increased 3-fold between 1975–2009 and the trend is still upwards. Despite moderate advances in treatment, most HCC patients present with advanced stage and have low survival (5-year <15%). Chronic hepatitis C (CHC) infection is the leading cause of HCC. The direct-acting antiviral (DAA) treatments offer cure from chronic infection. However, the subsequent risk of HCC persists in patients with CHC after virological cure. In fact, virologically-cured CHC is one of the most important emerging risk factors for HCC. While patients with advanced HCC have a median survival of less than 1 year, patients with early HCC who receive potentially curative therapy achieve 5-year survival rates near 70%. Early diagnosis, therefore, is critical to improved survival. However, the long-term harms and benefits of routine HCC surveillance in virologically cured CHC patients have not been evaluated. Furthermore, instead of using a one-size-fits-all approach, surveillance recommendations based on individualized risk factors could be more efficient — such an approach could detect HCC in early stages in high-risk patients and spare many non-HCC patients who do not need surveillance. The goals of this study are to: (1) identify the most salient protective and risk factors, and combine these factors in predictive models that differentiate high from low risk patients; (2) provide data on long-term benefits and harms of HCC surveillance tailored to individualized risk factors; and (3) develop a first publicly available decision support tool, HCC Simulator, for individualized surveillance recommendations.

2.KEYWORDS:

Hepatocellular carcinoma

Chronic hepatitis C

Direct-acting antivirals

Sustained viral response

Risk stratification

Protective factors

Risk factors

Risk prediction models

Benefits and harms

Decision support tool

Simulator tool

Cancer surveillance

3.ACCOMPLISHMENTS:

◦**What were the major goals of the project?**

The Statement of Work includes the following major goals:

Specific Aim 1 (Kanwal Lead): To examine determinants of HCC in virologically cured patients and develop a risk prediction model for HCC in these patients

Major Task 1: Examine determinants of HCC in patients virologically cured with direct acting antiviral (DAA) agents

Subtask 1: Data acquisition from VA Corporate Data Warehouse, data cleaning, variable creation, and cohort identification (Target date 2/28/2020) – 100% complete.

Subtask 2: EMR chart abstractions to confirm HCC (Target date 2/28/2020) – 100% complete.

Subtask 3: Data analysis of HCC predictors (Target date 4/30/2020) – 100% complete.

Major Task 2: Develop & optimize HCC risk prediction model

Subtask 1: Model fitting/Variable selection (Target date 06/30/20) – 100% complete.

Subtask 2: Risk stratification (Target date 07/31/20) – 100% complete.

Subtask 3: Subgroup sensitivity analysis (Target date 08/31/20) – 100% complete.

Specific Aim 2 (Chhatwal Lead, Kanwal Team Participating): To evaluate the benefits vs harms of HCC surveillance in virologically cured patients

Major Task 3: Develop a mathematical model simulating the natural history of HCC that incorporates risk estimates and key factors identified in Aim 1

Subtask 1: Model description – Develop a simulation model (individual-level state-transition model) of the natural history of HCC in virologically cured hepatitis C patients (Target date 08/31/20) – 100% complete.

Subtask 2: Add modules to the simulation model: surveillance and diagnosis, treatment options based on the BCLC stage at diagnosis (Target date 11/30/2020) – 100% complete.

Subtask 3: Liver transplantation - Extend simLT module to simulate the life course of HCC patients on the UNOS waiting list and after the transplant; we will also incorporate HCC recurrence (Target date 11/30/2020) – 100% complete.

Subtask 4: Costs and quality of life – Using published studies, estimate costs associated with the mathematical model's (simHCC's) states (Target date 12/31/2020) – 100% complete.

Major Task 4: Use simHCC to compare long-term effectiveness of no surveillance versus routine surveillance

Subtask 1: Generate a set of outcomes for surveillance vs no surveillance strategies for each risk group (Target date 01/31/21) – 100% complete.

Subtask 2: Conduct probabilistic sensitivity analysis (Target date 02/28/21) – 100% complete.

Subtask 3: Conduct value of information analysis (Target date 04/30/21) – 100% complete.

Specific Aim 3 (Chhatwal Lead, Kanwal Team Participating): To develop HCC Simulator, an online interactive tool for physicians and patients that provides the short- and long-term value of HCC surveillance in different risk groups

Major Task 5: Create a large dataset of hypothetical virologically cured patients

Subtask 1: Using simHCC model, simulate the life course of 1 million patients having different profiles (Target date 05/31/21) – 100% complete.

Subtask 2: Generate a set of graphical outcomes for each patient profile with and without HCC surveillance (Target date 06/30/21) – 100% complete.

Major Task 6: Create an online tool, HCC Simulator

Subtask 1: Create an online platform using RShiny (Target date 09/30/21) – 100% complete.

Subtask 2: Create a homepage for HCC Simulator (Target date 10/31/21) – 100% complete.

Subtask 3: Make the HCC Simulator available on the internet (Target date 11/30/21) – 100% complete.

Major Task 7: Conduct a feasibility to assess the usability of the HCC Simulator in a clinical setting

Subtask 1 (Chhatwal & Kanwal Teams Combined): Develop focus group and patient interview guides (Target date 12/31/21) – 100% complete.

Subtask 2: Provider and patient recruitment for focus groups and individual patient interviews (Kanwal Team); Conduct focus groups and individual patient interviews (Chhatwal Team Lead; Kanwal Team Supporting) (target date 03/31/22) – Delayed. 0% complete. Target date 03/31/2023.

Team A (Fasiha Kanwal Team): Dr. Kanwal's team will recruit all providers and patients for focus group sessions and individual patient interviews and will record the sessions and interviews.

Recruit, consent, and enroll 30 patients/human subjects for participating in 6 focus groups

Recruit, consent and enroll 20 providers for individual interviews

Team B (Chhatwal Team): Dr. Chhatwal's team will conduct the focus groups and individual patient interviews

Subtask 3 (Kanwal Team): Transcription services (Target date 04/30/22) – Delayed. 0% complete. Target date 04/30/2023.

Subtask 4: Coding and analysis of transcripts (Target date 05/31/22) – Delayed. 0% complete. Target date 05/31/2023.

Team A (Kanwal Team): Dr. Kanwal's team will review coding and analysis results

Team B (Chhatwal Team): Dr. Chhatwal's team will code and analyze transcripts

Major Task 8: Incorporate results from focus group and individual patient feedback into the HCC Simulator

Subtask 1: Re-design relevant components of the HCC Simulator based on the feedback (Target date 07/31/22) – Delayed. 0% complete. Target date 06/30/2023.

Team A (Kanwal Team): Dr. Kanwal's team will review results

Team B (Chhatwal Team): Dr. Chhatwal's team will modify the HCC Simulator

Subtask 2: Launch the HCC Simulator (Target date 08/31/22) – Delayed. 0% complete. Target date 06/30/2023.

Team A (Kanwal Team): Dr. Kanwal's team will serve as in a supporting/consulting role

Team B (Chhatwal Team): Dr. Chhatwal's team will launch the HCC Simulator

Major Task 9: Manuscripts and dissemination of results

Subtask 1: Organize a Webinar on use of the HCC Simulator (Target date 08/31/22) – Delayed. 0% complete. Target date 08/31/23.

Team A (Kanwal Team): Dr. Kanwal's team will participate in the development of the Webinar contents

Team B (Chhatwal Team): Dr. Chhatwal's team take the lead to organize a Webinar on its use

Subtask 2: Report project results through manuscripts in peer-reviewed journals (Target date 09/30/22) – Delayed. 70% complete. Target date 08/31/23.

1. Predictors of HCC in CHC patients with virologically induced cure – article accepted for publication – Kramer JR, Cao Y, Li L, Smith D, Chhatwal J, El-Serag HB, Kanwal F. Longitudinal associations of risk factors and hepatocellular cancer in patients with cured hepatitis C virus infection. In Press. Am J Gastroenterol.
2. Risk prediction model to identify patients at high risk for HCC after DAA induced virological cure – manuscript in progress
3. Cost-effectiveness of personalized HCC surveillance in virologically cured CHC patients – published – Mueller PP, Chen Q, Ayer T, et al. Duration and cost-effectiveness of

hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. J Hepatol. 2022;77(1):55-62. doi:10.1016/j.jhep.2022.01.027

4. When to stop HCC surveillance after virological cure with CHC – published – included in above article (doi:10.1016/j.jhep.2022.01.027)

5. What's the HCC incidence risk threshold above which surveillance is cost-effective? – manuscript in preparation (expected submission Oct 2022)

6. A brief report on HCC Simulator

Both Team A and Team B will participate collaboratively and equally in manuscript writing

◦ **What was accomplished under these goals?** The following was accomplished under these goals:

Specific Aim 1: To examine determinants of HCC in virologically cured patients and develop a risk prediction model for HCC in these patients.

Study Cohort. We included patients ≥ 18 years who achieved SVR with DAA in any of the 130 VA hospitals. We defined DAA treatment as ≥ 1 filled prescription of DAA (appendix 1) between 1/1/2014 and 12/31/2018. We used 3 months after the date of DAA completion as the index date for start of follow up to consider time needed to determine SVR. We classified patients as SVR if all HCV RNA tests were negative after the end of DAA treatment, with ≥ 1 HCV RNA test recorded at least 12 weeks after completion. If no test was available after 12-weeks we used a negative test from 4-12 weeks as SVR (6.9% of cohort). We excluded patients who failed to achieve SVR, who had HCC or liver transplant before or within 3 months of DAA treatment, had prior evidence of cancers with a high likelihood of liver metastases (esophageal, stomach, pancreatic, lung, kidney, breast cancer, and melanoma), and patients did not have evidence of ≥ 1 visit in the VA following end of treatment.

The study **outcome** was new cases of HCC after the date of completing DAA. HCC was defined based on 2 or more instances of ICD-9 (155.0) or ICD-10 codes (C22.0, C22.8, C22.9, D01.5) in CDW or any instance of HCC recorded in the CCR. We also reviewed electronic medical records of cases that had ICD codes but not included in CCR. We followed patients to the development of HCC, liver transplant, death, or last VA visit before December 31, 2021, whichever was earlier.

Predictor variables. These include age, sex, race/ethnicity, marital status, place of residence (rural vs. urban), HCV genotype, previous HCV treatment status, diabetes, hypertension, dyslipidemia, body mass index (BMI), active alcohol use disorder, smoking, and other medical and mental health comorbidity. . We also derived laboratory variables including values of bilirubin, AST, ALT, international normalized ratio, platelet tests, hemoglobin, creatinine, and sodium values. We also used FIB-4 to identify patients with cirrhosis/fibrosis at baseline (FIB-4 > 3.25) and used serial changes in FIB-4 to examine the decline or increase in fibrosis. All variables were longitudinal and time updating over time.

Statistical analysis. We used cause-specific Cox proportional hazard models for competing risks¹² constructed at three landmark times^{13, 14} (baseline, and 12- and 24-months after index) to examine the associations between risk factors measured at these landmark times and subsequent HCC risk, stratified by cirrhosis status at baseline.

We constructed six separate models (at three separate landmark times for patients with and without cirrhosis). The outcome was the time from the landmark to HCC. At each landmark, the data only included the at-risk patients at that time (e.g., those who are alive without HCC).

The predictor variables included time-independent and time-dependent defined at each landmark time. For continuous measures, we assessed both categorical and continuous values to determine the best performing measure. The predictors also incorporated longitudinal information of a patient up to the landmark time, including change in FIB-4 [defined as remained stable at low risk (≤ 3.25), increased from low (≤ 3.25) to high risk (> 3.25), declined from high (> 3.25) to low risk (≤ 3.25), or remained stable at high risk (> 3.25)] as well as changes in serum albumin, sodium, bilirubin, INR, creatinine, and hemoglobin between baseline and each landmark time. Log-transformation was used for variables with a skewed distribution. For model interpretability, we only considered two-way interactions that are frequently observed in the cohort or suggested by literature.

There was a small amount of missing data. We used multiple imputation generated from the fully conditional specification method of SAS PROC MI to create five imputed datasets and then combined the results using multiple imputation. Each imputed dataset went through a model building process with stepwise selection (entry p-value ≤ 0.10 ; retaining p-value ≤ 0.05). The final model included all predictors selected from at

least one dataset. For each landmark time, we forced baseline variable/s in the model if the final model/s included the corresponding change variable. Model fit with imputed datasets was checked using usual model checking procedures and no assumptions were violated.

We conducted 3 sensitivity analyses. We refined our cirrhosis definition by including only patients with a diagnosis of cirrhosis or its complications and excluding those with a FIB-4<1.45; we tested the robustness of our HCC definition by including patients with only 1 ICD code for HCC; and we examined the effect of BMI after excluding HCCs diagnosed in the first 12-months. **Specific objectives:** Our specific objectives were to acquire data from VA Corporate Data Warehouse and complete data cleaning, variable creation, and cohort identification; abstract EMR to confirm HCC; analyze data to identify predictors of HCC risk; develop and optimize HCC prediction models and perform subgroup analyses. We have completed these objectives.

Significant results: In total, 113,563 patients received DAA treatment between January 1, 2014, and December 31, 2018. We excluded 9112 without known SVR status, 1919 with prior HCC and 5034 with prior other cancers, 912 who received liver transplant, and 4019 who did not achieve SVR. Hence, our study cohort included 92,567 patients with SVR without prevalent HCC. The mean age of the overall cohort at baseline was 61.5 years (SD=7.55 year), 96.4% were men, 51.0% were white, and 38.7% were African American. A total of 26.5% had cirrhosis diagnosed at baseline and an additional 5.5% had a FIB-4 value greater than 3.25, 36.7% had diabetes, 83.1% had hypertension, 51.2% dyslipidemia, and 14.1% had an active alcohol use disorder. At baseline, 43.5% of patients with cirrhosis had diabetes; it increased to 46.4% at 24-month landmark time. Similarly, the proportion of patients with hypertension increased from 86.6% to 89.7% and dyslipidemia increased from 52.1% to 55.6% between baseline and 24-month landmark time. We found similar trends in patients without cirrhosis.

When examining changes in FIB-4 values from baseline to 24-months in patients with FIB-4 available at both time periods, 18.6% of patients with cirrhosis remained stable at high risk. In addition, 16.4% of patients had a high-risk FIB-4 at baseline that declined over time. FIB-4 values for few patients (3.5%) were low-risk at baseline but increased to high-risk. Approximately 61% with cirrhosis had low-risk FIB-4 values both at baseline and 24-months. In patients without cirrhosis where everyone had low FIB-4 at baseline, 97.8% remained stable at low-risk and 2.2% increased from low to high risk at 24-months.

There were 3,247 incident cases of HCC diagnosed during mean 2.51 (SD=1.66) years of follow-up (maximum 7.11 years); 74.0% (n=2,404) were diagnosed in patients with cirrhosis at baseline. In 29,398 patients with cirrhosis, cumulative incidence of HCC was 2.0%, 3.8%, and 5.4% at 1, 2 and 3 years, respectively. In contrast, HCC risk was considerably lower in 63,169 patients without cirrhosis in whom 843 were diagnosed with HCC (0.2%, 0.5%, and 0.8%, respectively) (p-value <0.0001).

In the baseline model, in patients with cirrhosis, the risk of HCC was higher in men (adjusted hazard ratio (HR) =1.89, 95% confidence interval (CI)=1.37-2.59) and lower in African American patients (HR=0.78, 95%CI=0.71-0.86). Patients with genotype 3 had a higher risk of HCC (HR=1.47, 95%CI=1.27-1.71) than those with other genotypes. Patients with a longer duration since cirrhosis diagnosis had higher risk (≥ 5 years vs. <1 year, HR=1.71, 95%CI=1.46-2.00). Serum bilirubin, albumin, presence of varices, and higher FIB-4 were associated with HCC risk. Specifically, HCC risk was 2.5-fold higher (95%CI, 2.11-2.94) in cirrhosis patients who also had FIB-4 >3.25 than those with FIB-4 values <1.45. Patients who were current smokers had an increased risk for HCC than non-smokers (HR=1.32, 95%CI=1.16-1.51). None of the pre-specified interaction terms were significant in the adjusted model at baseline.

Most of the associations observed at baseline persisted in direction and magnitude at 12- and 24-month landmark times, with few notable exceptions. Presence of ascites was associated with an increased risk for HCC at both 12- and 24-months. Changes in serum albumin, bilirubin, and FIB-4 between baseline and landmark times were strongly associated with subsequent risk of HCC. For example, one unit increase in serum bilirubin between baseline and 24-month landmark time was associated with a 22% increase in HCC risk. Compared with patients with persistently low FIB-4 at baseline and 24-months, the risk of HCC was almost 2-fold higher in patients who had persistently high FIB-4 at the time of virological cure and at 24-months (HR=1.70, 95%CI, 1.45-2.00) and 81% higher in patients who were at low risk (FIB-4 $\leq$ 3.25) but increased to high risk (FIB-4>3.25) at 24-months (HR = 1.81, 95% CI = 1.37-2.38). Results were similar in the sensitivity analyses excluding cirrhosis patients with FIB-4<1.45 and including patients with 1 ICD code for HCC.

In patients without cirrhosis, patients with hypertension and diabetes had a 1.5-fold higher risk of HCC than their counterparts. After controlling for diabetes and hypertension, there was no difference in the risk of HCC between patients with BMI higher than 30 compared with BMI 25-30. Risk of HCC was higher in patients with BMI <25, with the highest risk in patients with BMI <18.5 compared with BMI 25-<30, (HR=1.93,

95%CI=1.20-3.12). The risk of HCC for BMI <18.5 was slightly attenuated after excluding patients with HCC in 12-months after index date. Baseline serum albumin and FIB-4 were associated with HCC risk. Patients with baseline FIB-4 between 1.45 and 3.25 had 2.3-fold higher risk of HCC than those with low FIB-4 <1.45 (HR=2.27, 95%CI=1.96-2.63). Prior failure of HCV treatment, HCV genotype 3, and current smoking were also associated with HCC risk in patients without cirrhosis.

Only metabolic traits (diabetes, hypertension) and change in FIB-4 remained associated with HCC risk at all landmark times. At 24-month landmark time, patients with hypertension and diabetes had 1.7 to 1.5-fold higher risk of HCC than their counterparts. Patients who had an increase from FIB-4 of low risk at baseline to high risk at 24-month landmark time had 3-fold increase in HCC risk (HR=3.12, 95%CI, 2.12-4.60).

Following the 24-month landmark time, the 3-year cumulative incidence of HCC varied from 3.4% (95%CI, 3.1%-3.7%) in patients who had persistently low FIB-4 value to 9.2% (95%CI, 8.3%-10.2%) in patients with persistently high FIB-4. Risk of HCC was low in all subgroups without cirrhosis, with few notable exceptions. In patients who increased from low to high risk, the 2- and 3-year cumulative incidence of HCC was 2.4% (95%CI, 1.6%-3.6%) and 3.0% (95%CI, 2.1%-4.4%), respectively. Cumulative 1, 2- and 3-year risk of HCC in 419 patients without cirrhosis who had hypertension, diabetes and who experienced an increase from low to high risk between baseline and 24-month landmark was 3.1%, 5.7%, and 7.2%, respectively.

The AUCs for the models in patients with and without cirrhosis were 0.72 (95% CI, 0.70-0.74) and .0.68 (95% CI, 0.66-0.70), respectively.

Specific Aim 2: To evaluate the benefits vs harms of HCC surveillance in virologically cured patients
For Specific Aim 2, **the major activities** undertaken by the Chhatwal Team, with participation from the Kanwal Team, in Year 2 included developing a mathematical model simulating the natural history of HCC to evaluate the benefits and harms of routine HCC screening in virologically cured patients. We included the following new modules in year 2: surveillance and diagnosis; treatment options based on the BCLC stage at diagnosis; costs associated with HCC surveillance, hepatitis C sequelae, liver transplant and other HCC treatments. We also extracted quality of life associated with all health states in the model. Using this extended model, we conducted three studies.

Study 1

We evaluated the cost effectiveness of HCC surveillance in hepatitis C cured patients. Primary outcomes included life expectancy, quality-adjusted life years (QALYs), total costs, and incremental cost-effectiveness ratio (ICER) of each of the simulated surveillance strategies.

Preliminary results: In virologically-cured patients with cirrhosis, the ICER of biannual surveillance remained below \$100,000/QALY (range: \$85,000-\$98,100) when surveillance was stopped at age 65, rising above \$100,000 if surveillance continued beyond 65. For every 1000 patients, surveillance detected 260 HCCs in 'very early'/early stage, and 120 in intermediate/advanced stage. In contrast, no surveillance detected 92 HCCs in 'very early'/early stage, and 274 in intermediate/advanced stage. Compared to no surveillance, HCC surveillance provided QALY gains of 47 per 1000 patients. In virologically-cured patients with advanced fibrosis, the ICER of biannual surveillance remained above \$100,000 irrespective of the stopping age.

Conclusion: Biannual surveillance for HCC in virologically-cured hepatitis C patients with cirrhosis is cost-effective until the age of 65.

Study 2

The AASLD guidance recommends biannual surveillance for hepatocellular carcinoma (HCC) in hepatitis C virus (HCV) infected individuals with cirrhosis if HCC incidence is above 1.5 per 100 person-years (PY). However, the incidence threshold for surveillance in cirrhosis individuals who achieved virological cure with direct-acting antivirals is unknown. Using our microsimulation model, we estimated the HCC incidence above which routine HCC surveillance is cost-effective in this growing population of individuals with virologically cured HCV.

We developed a Markov-based microsimulation model of the natural history of HCC in individuals with hepatitis C who achieved virological cure with oral direct-acting antivirals. We used published data on the natural history of hepatitis C, competing risk post virological cure, HCC tumor progression, real-world HCC surveillance adherence, contemporary HCC treatment options and associated costs, and utilities of different health states. We estimated the HCC incidence above which biannual HCC surveillance using ultrasound and alpha-fetoprotein would be cost-effective.

In virologically cured hepatitis C individuals with cirrhosis and advanced fibrosis, HCC surveillance is cost-effective if HCC incidence exceeds 0.7 per 100-PY using \$100,000 per quality-adjusted life-year (QALY) willingness-to-pay. At this HCC incidence, routine HCC surveillance would result in 2,650 and 5,700 additional life-years per 100,000 cirrhosis and advanced fibrosis persons, respectively, compared to no surveillance. At \$150,000 willingness-to-pay, surveillance is cost-effective if HCC incidence exceeds 0.4 per 100-PY. Sensitivity analysis showed that the threshold mostly remained below 1.5 per 100-PY.

Conclusion. Our study suggests that for patients with virologically cured hepatitis C, routine surveillance is warranted above the HCC incidence threshold of 0.7 per 100-PY, which is lower than the previous 1.5% incidence value used to guide HCC surveillance decisions. Updating clinical guidelines could improve the early diagnosis of HCC. Use of this revised threshold could increase HCC surveillance for hepatitis C patients, providing an opportunity for earlier diagnosis and treatment.

Study 3

We also conducted probabilistic sensitivity analysis and value of information analysis to evaluate the impact of uncertainty of HCC surveillance recommendations. Preliminary results are being analyzed and will be finalized in soon for submission to a journal.

Specific Aim 3: To develop HCC Simulator, an online interactive tool for physicians and patients that provides the short- and long-term value of HCC surveillance in different risk groups

For Specific Aim 3, the **major activities** undertaken by the Chhatwal Team, with participation from the Kanwal Team, in Year 3 included the following.

Using the mathematical model, we simulated the life course of hypothetical patients with different risk profiles and stored them in a database. The dataset included cause of death (liver-related, or non-liver-related), development of HCC overtime, and likelihood of detection of HCC with or without surveillance.

We used the above database to create an online, interactive framework, which allows users to enter specific patient profiles and generate model-predicted long-term outcomes in graphical format. We use RShiny, an R package to develop an interactive online interface of the HCC Simulator. Figure shows the screenshots of Liver Cancer Simulator.

[About Liver Cancer](#)
[Team](#)
[About The Simulator](#)
[Simulator](#)

Choose Risk Factors

Current Age: ?

40 44 48 52 56 60 64 68 72 75

Sex: ?

☒ Male

☐ Female

Race

☒ Black

☐ Hispanic

☐ Other

Fibrosis Stage

☐ Advanced Fibrosis

☒ Cirrhosis

Additional Risk Factors: ?

☐ Diabetes Diagnosis

☐ Hypertension Diagnosis

☐ Alcohol Use

Run Simulator

Tool Introduction and Description

Simulator Purpose:

The Liver Cancer Simulator is an interactive tool that allows patients and physicians to simulate the potential health outcomes for a specific patient with their unique demographic profile. This tool can be used to evaluate the risk of developing liver cancer and to identify the benefits of regular screening for a particular individual.

Tool Overview:

To use the simulator, please input the patient's personal risk factors in the panel to the right. Once your selections have been made, please click the 'run simulator' button to generate the results.

Key Terms:


- Surveillance** - This refers to a patient undergoing screening with a medical professional. The aim of surveillance is to detect any cancer at the earliest stage possible.
- Risk Factors** - Any personal characteristic that may impact the occurrence or progression of liver cancer is considered a risk factor in this simulator.
- Liver Cancer** - Liver cancer is a type of cancer that starts in the liver. Hepatocellular carcinoma (HCC) is the most common type of liver cancer.
- Liver Cirrhosis** - Cirrhosis is a permanent and end-stage liver disease that occurs due to the accumulation of scar tissue in the liver. Causes of liver cirrhosis include chronic alcohol abuse and hepatitis among others.

Intro My Chance of Getting Liver Cancer?

[Why is this important?](#) ?

Your 10-Year Chance of
Developing Liver Cancer:

👉 18 out of 100 People
Like You



What Are My Chances of Surviving Liver Cancer?

5-Year Survival by Cancer Stage at Diagnosis

[Why is this important?](#) ?

Early

56%

Intermediate

24%

Late

5%

Survival after 5 years is highly related to the stage of the liver cancer at diagnosis. On average, individuals diagnosed at an early stage have the highest 5-year survival rate with treatment.

How Much Will I Benefit From Getting Screened?

[Why is this important?](#) ?

Regular Screening Improves Early Detection

👉 Undergoing regular screening makes it **26 times more likely** that a potential cancer would be found in an early stage.

Without Screening

2% of
Cancers are
Detected Early



With Screening

51% of
Cancers are
Detected Early



What is the Importance of
Detecting Cancer Early?

👉 Your chances of surviving 5 years after a cancer is detected are **11 times greater** if the cancer is detected in the early stage, instead of the late stage.

◦**What opportunities for training and professional development has the project provided?**

Two student analysts got an opportunity to gain knowledge of the natural history of HCC in hepatitis C cured patients. This knowledge was transferred in the development of Liver Cancer Simulator, which is intended to be used by patients to understand the risk factors of HCC and importance of early detection of HCC to improve patients survival.

◦**How were the results disseminated to communities of interest?**

The results were disseminated via meeting presentations and manuscripts.

◦**What do you plan to do during the next reporting period to accomplish the goals?**

We received approval for a no cost extension through 08/31/2023 and expect to complete Major Tasks 7, 8 and 9 during this timeframe.

Major Task 7 (conduct a usability study of the on-line simulator) – Both teams will work together to conduct user-centered design assessments of the Liver Cancer Simulator with patients and feasibility testing with patients and providers to assess usability of the simulator in clinical settings. As part of a user-centered design process, we will initially elicit patients' perceptions on the design and understandability of the simulator as a decision support tool using focus groups. Themes arising from the focus groups will inform the design of a live prototype of the Liver Cancer Simulator. The team will then conduct individual, Think-Aloud interviews with patient and providers to elicit usability of the simulator. Themes from patient and provider interviews will inform refinements to the final design as needed, before wide-spread dissemination. The team has built this tool with the goal of expanding the use of the program beyond specialists (e.g., hepatologists and gastroenterologists) and patients at risk of developing liver cancer.

Kanwal Team – The Kanwal team will recruit participants, record interviews and coordinate transcription.

Chhatwal Team – The Chhatwal team will conduct the interviews (via video-teleconference), analyze transcript data, and summarize usability feedback.

Major Task 8 – The Chhatwal team will complete Major Task 8 to modify the on-line liver cancer simulator.

Major Task 9 (manuscripts and dissemination of results) – Both teams will work together to organize a Webinar on the use of the Liver Cancer Simulator. Both teams will work together to finalize the manuscript publications that are now in process. Target date 08/31/23.

4.IMPACT: Our study provides evidence from a well characterized cohort of virologically cured patients with HCV but free of cirrhosis that monitoring changes in FIB-4 might have clinical utility, especially in patients with co-existing diabetes and hypertension. In patients with cirrhosis, evolution of FIB-4 and other select markers of liver disease severity could refine risk stratification. We believe risk assessment based on repeat measurements at 2 years is practical and can improve shared decision-making between patients and their physicians by providing a quantifiable personalized HCC risk assessment, including how it changes over time. These findings may guide clinical practice guidelines about management of patients with virologically cured HCV.

5.CHANGES/PROBLEMS:

◦**Changes in approach and reasons for change**

Nothing to Report.

◦**Actual or anticipated problems or delays and actions or plans to resolve them**

Both teams experienced delays related to the IRB approval process at both sites involving changes required for the MGH team qualitative expert to conduct interviews with provider and patient participants at the Houston site. A SMART IRB agreement had to be established and protocols at both locations needed to be amended. First, MGH IRB reviewed and approved the changes on 06/30/2022. Then, the Houston IRB began its review

and is in the final stages of approval. After Houston IRB approval is received, the teams will seek HRPO approval. The IRB approval process delays have caused a delay in the team's ability to begin Major Task 7 – To conduct a feasibility study to assess the usability of the HCC Simulator in a clinical setting and Major Task 8 – Incorporate results from focus group and individual patient feedback into the HCC Simulator. We received approval of a no cost extension through 08/31/2023 and expect to complete Major Tasks 7, 8 and 9 during this timeframe.

◦**Changes that had a significant impact on expenditures**

Chhatwal Team – Nothing to report. No change in the scope of work is planned.

Kanwal Team – Nothing to report. No change in the scope of work is planned.

◦**Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

Nothing to Report.

6.PRODUCTS:

◦**Publications, conference papers, and presentations**

Mueller PP, Chen Q, Ayer T, Nemutlu G, Bethea ED, Peters MLB, Lee B, Nanjua NZ, Kanwal F, Chhatwal J. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. J Hepatol. 2022;77(1):55-62. doi:10.1016/j.jhep.2022.01.027 Epub 2022 Feb 12. PMID: 35157959. Acknowledgement of Federal support reported.

Kramer JR, Cao Y, Li L, Smith D, Chhatwal J, El-Serag HB, Kanwal F. Longitudinal associations of risk factors and hepatocellular cancer in patients with cured hepatitis C virus infection. In Press. Am J Gastroenterol. Acknowledgement of Federal support reported.

■**Books or other non-periodical, one-time publications.**

Nothing to report.

■**Other publications, conference papers, and presentations.**

Kramer JR, Cao Y, Li L, Smith D, Chhatwal J, El-Serag HB, Kanwal F. Longitudinal associations between risk factors and subsequent risk of hepatocellular cancer in patients with hepatitis C virus infection and virological cure. 2021 AASLD The Liver Meeting, November 12-15th. Anaheim, CA.

Chhatwal J, Hajjar A, Mueller PP, Nemutlu G, Peters MLB, Kanwal F. Hepatocellular Carcinoma Incidence Threshold for Routine Surveillance is Much Lower in Hepatitis C Cirrhosis Individuals Who Achieve Virological Cure. 2021 AASLD The Liver Meeting, November 12-15th. Anaheim, CA. Also accepted for inclusion in the Best of The Liver Meeting's summary slide deck in the Health Services and Public Health Research category.

Nemutlu G, Mueller PP, Qiushi Chen, Turgay Ayer, Naveed Janjua, Kanwal F, Chhatwal J. Liver Cancer Surveillance in the Era of New Hepatitis C Antiviral Treatments: A Value of Information Analysis. 2021 INFORMS Annual Meeting, October 27-27th 2021. Anaheim, CA.

◦**Website(s) or other Internet site(s)**

https://analytics-tools.shinyapps.io/HCC_Simulator_2/

The Liver Cancer Simulator is an interactive tool that allows patients and physicians to simulate the potential health outcomes for a specific patient with their unique demographic profile. This tool can be used to evaluate the risk of developing liver cancer and to identify the benefits of regular screening for a particular individual.

◦**Technologies or techniques**

Nothing to report.

◦**Inventions, patent applications, and/or licenses**

Nothing to report.

◦**Other Products**

Nothing to report.

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

◦**What individuals have worked on the project?**

Name: Fasiha Kanwal, MD, MSHS

Project Role: Principal Investigator

Researcher Identifier (e.g. ORCID ID): <https://orcid.org/0000-0001-6715-3966>

Nearest person month worked: 2.4

Contribution to Project: As the Principal Investigator, Dr. Kanwal oversees all aspects of the project and has primary responsibility for supervising Aim 1 activities: 1) Data acquisition, data cleaning, variable creation, cohort identification, 2) EMR chart abstractions to confirm HCC, 3) data analysis of HCC predictors, 4) develop and optimize HCC risk prediction model.

Funding Support:

Name: Jennifer R. Kramer, PhD

Project Role: co-Investigator

Researcher Identifier (e.g. ORCID ID): <https://orcid.org/0000-0003-2953-4949>

Nearest person month worked: 2

Contribution to Project: Dr. Kramer is leading the Data Analysis Team based at the VA (Aim 1 to examine determinants of HCC in virologically cured patients and develop a risk prediction model for HCC in these patients). She works closely with the PI, the biostatistician, and the data analyst on data acquisition, and operationalizing study variables. She supervises chart abstractors, oversees data analysis, and interprets results.

Funding Support:

Name: Roxanne Desiderio, BS

Project Role: Research Assistant

Researcher Identifier (e.g. ORCID ID):

Nearest person month worked: 6

Contribution to Project: Ms. Desiderio conducted electronic medical record (EMR) chart reviews and assisted with administrative tasks, such as meeting scheduling, reporting, and maintaining regulatory documentation.

Funding Support:

Name: Yumei Cao, MS

Project Role: Data Analyst

Researcher Identifier (e.g. ORCID ID):

Nearest person month worked: 6

Contribution to Project: Ms. Cao is the data analyst for Aim 1 of the project, responsible for the build and upkeep of the study databases, quality control measures, and conducting statistical analyses with the guidance of Drs. Kramer, Richardson, and Kanwal. She performed the programming required to identify the cohort, define the study variables, and construct analytic datasets. Ms. Cao provided weekly summary reports on the state of data analysis at the weekly project meeting headed by Dr. Kanwal (PI).

Funding Support:

Name: Donna Smith, MEd

Project Role: Project Coordinator

Researcher Identifier (e.g. ORCID ID): <https://orcid.org/0000-0003-1906-666X>

Nearest person month worked: 3

Contribution to Project: Ms. Smith is responsible for all administrative and regulatory tasks of the project, including IRB protocol approvals, renewals, and amendments; organizing project team meetings; maintaining study binders; and managing the budget. She coordinates data acquisition requests and data use agreement renewal updates. She will work closely with the core research investigators to coordinate writing and editing of progress reports and will assist with the development and publication of dissemination products.

Funding Support:

Name: Chris Williams, BS

Project Role: IT Manager

Researcher Identifier (e.g. ORCID ID):

Nearest person month worked: 1

Contribution to Project: Mr. Williams is responsible for performing computer server maintenance and upgrades. He provides support and training for study personnel on project-related software programs. He ensures that data privacy standards are maintained and processes Data Use Agreements and PKI for study personnel. These functions are critical part of our data-management security plan to ensure compliance and the safety of all encrypted veteran data.

Funding Support:

Name: Jagpreet Chhatwal, PhD

Project Role: Principal investigator

Researcher Identifier (e.g. ORCID ID): <https://orcid.org/0000-0001-8741-4430>

Nearest person month worked: 2

Contribution to Project: As the Principal Investigator, Dr. Chhatwal has primary responsibility for supervising Aim 2 activities: development of the mathematical model to simulate the natural history of HCC in hepatitis C cured patients, literature review, validation and analysis of the proposed model.

Funding Support:

Name: Ali Hjaar, PhD

Project Role: Postdoc

Researcher Identifier (e.g. ORCID ID):

Nearest person month worked: 6

Contribution to Project: Dr. Hjaar is a postdoctoral fellow who developed the natural history model of hepatitis C and HCC using a programming language. He also assisted with estimation model inputs and analysis of outcomes.

Funding Support:

Name: Neeti Kulkarni,

Project Role: Analyst

Researcher Identifier (e.g. ORCID ID):

Nearest person month worked: 6

Contribution to Project: Ms. Kulkarni is a research analyst responsible for conducting literature review of model parameters to evaluate the cost effectiveness of HCC screening in hepatitis C cured persons.

Funding Support:

Name: Alec Aaron,

Project Role: Programmer Analyst

Researcher Identifier (e.g. ORCID ID):

Nearest person month worked: 3

Contribution to Project: Mr. Aaron is a programmer analyst responsible for developing an online tool to inform HCC screening for patients and providers. He developed the interface of the Liver Cancer Simulator and downloadable reports.

Funding Support:

Name: Mary Ann Ladd, BS

Project Role: Data Manager

Researcher Identifier (e.g. ORCID ID):

Nearest person month worked: 1

Contribution to Project: Ms. Ladd is the Systems Manager of the MGH Institute for Technology Assessment. She was responsible for overseeing the integration and day-to-day management of computer systems at the Institute for Technology Assessment, and for facilitating electronic communications among collaborators. She worked with the other team members to facilitate data extraction and storage, and ensure that all study data are secure, adequately stored and backed up.

Funding Support:

Name: Peter Mueller, PhD

Project Role: Research Scientist

Researcher Identifier (e.g. ORCID ID):

Nearest person month worked: 3

Contribution to Project: Dr. Mueller is a research scientist who assisted with the development of the natural history model of hepatitis C and HCC using a programming language, setup of the computer server for computational runs for the model. He also assisted with the analysis of outcomes.

Funding Support:

◦Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

PREVIOUS, CURRENT, AND PENDING SUPPORT (PCPS)

KANWAL, FASIHA

PREVIOUS

Title: HSR&D Project # IIR 16-075 (Application # 1 I01 HX002204-01A2) Patient Centered Care for Individuals with Advanced Liver Disease

Role on project: MPI

AIMS: 1) To develop risk stratification models of advanced liver disease (AdvLD) prognosis; 2) To describe patients' experiences and goals of AdvLD care; 3) To identify clinicians' perceptions of opportunities and barriers to patient-centered AdvLD care.

Time Commitment (Level of Effort): 0 calendar months

Supporting Agency: VA HSR&D

Name and address of funding agency's Grant's Officer:

Cathie Plouzek, PhD, PMP

Health Services Research and Development (10P9H)

Office of Research and Development, VA Central Office

Department of Veterans Affairs

810 Vermont Avenue NW

Washington, DC 20420

E-mail: cathie.plouzek@va.gov

Performance Period: 05/2018-04/2021 (NCE 05/2021-04/2022)

Level of funding:

Brief description of project's goals: The main goal of the project is to develop a patient-centered care model for advanced liver disease, including risk-prediction models and clinician-patient collaborative treatment planning guides that focus on addressing patient unmet needs and expectations about illness course and care preferences for curative, supportive, and palliative care. The study findings will have direct impacts on current advanced liver disease care, as well as provide evidence for developing innovative care models for other serious chronic illnesses.

% Overlap: None

CURRENT

Title: NIDDK P30 DK 56338-10/15 Center for Gastrointestinal Development, Infection and Injury

Role on project: Co-director (Overall PI: El-Serag)

AIMS: 1) To serve clinical and basic science investigators in digestive diseases with comprehensive study design consultation and support; 2) To assist DDC investigators in all aspects of the acquisition of clinical specimens required for their research in digestive diseases; 3) To support comprehensive data analyses and interpretation of basic, translation, clinical and epidemiological studies.

Time Commitment (Level of Effort): 0.6 calendar months

Supporting Agency: NIH/National Institute of Diabetes and Digestive and Kidney Diseases

Name and address of funding agency's Grant's Officer:

Peter J Perrin

Program Official

Division of Digestive Diseases and Nutrition, NIDDK, NIH

6707 Democracy Blvd., Room 6015

Bethesda, MD 20892-5450

Email: Peter.Perrin@nih.hhs.gov

Performance Period: 12/1999-02/2023

Level of funding:

Brief description of project's goals: This Center supports four scientific cores, conferences and a pilot project program to facilitate on-going Digestive Disease research of center members, promote interactions and translational research between basic and clinical areas, develop new projects, nurture new investigators, and provide GI educational activities.

% Overlap: None

Title: 1 U01 CA230997-01 Risk Stratification for and Early Detection of Liver Cancer

Role on project: PI

AIMS: 1) Develop and test novel personalized risk stratification indices for predicting future HCC development in cirrhosis from diverse etiologies; 2) Develop and evaluate an algorithm combining existing HCC blood based biomarkers (AFP, AFPL3, DCP), their longitudinal changes and host features (e.g., cirrhosis etiology) to improve early HCC detection; 3) Evaluate novel plasma-based methylation markers for cell-free DNA (MDMs) as an independent surveillance biomarker for early HCC detection. Using the PROBE design, we will test 12 individuals MDMs identified in Phase 2 study.

Time Commitment (Level of Effort): 1.8 calendar months

Supporting Agency: NIH Consortium on Translational Research in Early Detection of Liver Cancer:

Translational Research Centers (U01)

Name and address of funding agency's Grant's Officer:

Viviana Knowles

National Cancer Institute

Office of Grants Administration

9609 Medical Center Drive

West Tower, 2nd floor

Rockville MD 20850

viviana.knowles@nih.gov

Performance Period: 09/2018-08/2023

Level of funding:

Brief description of project's goals: The overarching goal of our Translational Research Center (TRC) is to reduce the mortality of hepatocellular cancer (HCC) by developing personalized indices that combine novel and existing biomarkers with clinical, behavioral and genetic data to improve clinical risk stratification and increase early detection of HCC.

% Overlap: None

Title: PR181562 Risk of hepatocellular cancer after virological cure with direct acting antiviral agents in individuals with hepatitis C (subject grant)

Role on project: MPI

AIMS: 1) To examine determinants of HCC in virologically cured patients and develop a risk prediction model for HCC in these patients; 2) To evaluate benefits versus harms of HCC surveillance in virologically cured patients; 3) To develop HCC Simulator, an online interactive tool for physicians and patients that provides the short- and long-term value of HCC surveillance in different risk groups.

Time Commitment (Level of Effort): 0.05 calendar months

Supporting Agency: Department of Defense Office of Congressionally Directed medical Research Programs (CDMRP)

Name and address of funding agency's Grant's Officer:

Claudio Ortiz, Ph.D.

Science Officer, Goldbelt Frontier

Congressionally Directed Medical Research Programs (CDMRP)

US Army Medical Research Materiel Command (USAMRMC)

1077 Patchel Street

Fort. Detrick, MD 21702-5024

Email: claudio.d.ortiz.ctr@mail.mil

Performance Period: 09/2019-08/2022; 09/2022-08/2023 (NCE)

Level of funding:

Brief description of project's goals: The goal of this study is to examine the risk and determinants of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C (CHC) virologically cured with new direct acting antiviral agent (DAA) regimens and to identify cost-effective strategies for early detection of HCC in those patients.

% Overlap: None

Title: Cirrhosis Quality Collaborative

Role on project: co-PI (Corresponding co-PI: Volk)

AIMS: Phase 1: Design phase and network development. Aim 1a: Design a collaborative chronic care network that involves stakeholders at all levels in the design process. Aim 1b: Engage clinician, patient and policy stakeholders to refine a parsimonious set of quality measures – including patient-reported outcomes (PRO's). Phase 2: Software build and network pilot. Aim 2a: Work with ArborMetrix to build the data registry. Aim 2b: Prospectively collect data on the set of quality measures across 10 sites, to identify variation in process, outcome, and patient reported measures of cirrhosis care. Aim 2c: Pilot test a rapid-cycle quality improvement project on a single focused target.

Time Commitment (Level of Effort): 0.05 calendar months

Supporting Agency: American Association for the Study of Liver Diseases

Name and address of funding agency's Grant's Officer:

Julie Deal

Interim CEO, American Association for the Study of Liver Diseases

1001 N. Fairfax Street, #400

Alexandria, VA 22314

Performance Period: 09/2018-08/2023

Level of funding:

Brief description of project's goals: This is the first large-scale quality improvement project targeting patients with advanced and chronic liver diseases. It will pilot test a collaborative chronic care network, including necessary technology infrastructure.

% Overlap: None

Title: The Texas Collaborative Center for Hepatocellular Cancer

Role on project: co-Investigator

AIMS: Aim 1/Year 1: Support and enhance research collaborations among CAP researchers by providing multiple levels of connectivity and necessary research support. Aim 2/Year 2: To set up the framework to educate healthcare providers, researchers, and the public on best practices and to engage private and public entities in policy considerations. Aim 3/Year 2: To engage all stakeholders and solicit strategies to improve HCC-related prevention and care and best disseminate those improvements. Aim 4/Years 3-5: To begin disseminating results on best practices and new opportunities that will impact HCC burden in Texas.

Time Commitment (Level of Effort): 0.6 calendar months

Supporting Agency: Cancer Prevention & Research Institute of Texas (CPRIT)

Name and address of funding agency's Grant's Officer:

General CPRIT Contact Information:

Email: cprit@cprit.state.tx.us

Cancer Prevention and Research Institute of Texas

1701 North Congress Avenue, Suite 6-127

Austin, TX 78701

Performance Period: 08/2019-02/2024

Level of funding:

Brief description of project's goals: The Collaborative Action Program (CAP) goal is reducing liver cancer mortality in Texas. To maximize the impact of CAP awards, we propose the creation of the Texas Collaborative Center for Hepatocellular Cancer (TeCH), which will have a robust Administrative Core and an External Advisory Committee and house infrastructure to facilitate CAP research activities, foster cross-project collaboration, and disseminate emerging findings.

% Overlap: None

Title: CPRIT RP200633 Reducing Disparities in the Risk of Hepatocellular Cancer

Role on project: MPI

AIMS: 1) Examine the role of individual, inter-personal and community level factors in explaining racial/ethnic disparities in cirrhosis progression to HCC (prevention); 2) Examine the role of individual, inter-personal and community level factors in explaining racial/ethnic disparities in HCC tumor stage at diagnosis (early detection); 3) Identify specific targets for future interventions to reduce racial/ethnic HCC disparities.

Time Commitment (Level of Effort): 1.5 calendar months

Supporting Agency: Cancer Prevention & Research Institute of Texas (CPRIT)

Name and address of funding agency's Grant's Officer:

General CPRIT Contact Information:

Email: cprit@cprit.state.tx.us

Cancer Prevention and Research Institute of Texas

1701 North Congress Avenue, Suite 6-127

Austin, TX 78701

Performance Period: 08/2020-08/2025

Level of funding:

Brief description of project's goals: The primary objective of this study is to identify in a large racial/ethnically and socioeconomically diverse cohort of patients with cirrhosis the multi-level factors that explain racial and ethnic disparities in HCC risk/incidence and tumor stage at diagnosis, as well as a set of potentially actionable (identifiable, preventable or treatable) determinants of HCC disparities in Texas.

% Overlap: None

Title: 1R01CA256977 Multi-level Evaluation of Racial/Ethnic Disparities in Liver Disease Outcomes **Role on project:** MPI

AIMS: 1) Examine the contribution of individual-, interpersonal-, and community-level factors to racial/ethnic and socioeconomic disparities in cirrhosis progression to hepatic decompensation, including HCC; 2) Identify individual-, interpersonal-, and community-level determinants of racial/ethnic and socioeconomic disparities in liver-related hospitalization; 3) Characterize the contribution of individual-, interpersonal-, and community-level factors to racial/ethnic and socioeconomic disparities in overall survival of patients with cirrhosis.

Time Commitment (Level of Effort): 1.8 calendar months

Supporting Agency: National Institutes of Health

Name and address of funding agency's Grant's Officer:

Rina Das, PhD

National Institute on Minority Health and Health Disparities (NIMHD (<https://www.nimhd.nih.gov/>)) Telephone:

301-496-3996

Email: dasr2@mail.nih.gov (mailto:dasr2@mail.nih.gov)

Performance Period: 03/2021-02/2026

Level of funding:

Brief description of project's goals: To conduct a comprehensive evaluation of multilevel factors hypothesized to play important roles in causing racial/ethnic and SES disparities in three key measures of cirrhosis prognosis: a) hepatic decompensation, including HCC, b) liver-related hospitalization, and c) overall survival.

% Overlap: None

Title: RP200554 A Novel Risk Stratification and Early Detection Strategy to Reduce Liver Cancer Mortality (New)

Role on project: co-Investigator

AIMS: 1) Develop and validate risk stratification models using EMR data to risk stratify cirrhosis patients for developing HCC; 1b) Compare the performance of risk stratification models using EMR data alone to one incorporating EMR data, patient factors and a serum-based molecular signature panel; 2) Characterize the performance of the Glycotest Panel for early HCC detection, in a phase III surveillance biomarker study among patients with cirrhosis.

Time Commitment (Level of Effort): 1.2 calendar months

Supporting Agency: Cancer Prevention & Research Institute of Texas (CPRIT)

Name and address of funding agency's Grant's Officer:

General CPRIT Contact Information:

Email: cpriti@cpriti.state.tx.us

Cancer Prevention and Research Institute of Texas

1701 North Congress Avenue, Suite 6-127

Austin, TX 78701

Performance Period: 08/2021-08/2025

Level of funding: of project's goals: To improve the approach to risk assessment and early detection of liver cancer as two high priority targets to reducing liver cancer mortality.

% Overlap: None

Title: 1P01CA263025-01A1 Prevention of Hepatocellular Carcinoma Related to Metabolic Syndrome, Project 2 (new)

Role on project: Project Lead, Project #2

AIMS: 1) To examine the chemopreventive effects for each of metformin, statins, and glitazones in reducing the risk of incident HCC among individuals with MAFLD; 2) To measure potential harms of metformin, statins and glitazones in individuals with MAFLD; 3) To examine the modifying effects of genetic markers on chemopreventive benefits of metformin and statins in a high-risk group of patients with MAFLD cirrhosis. **Time**

Commitment (Level of Effort): 0.36 calendar months

Supporting Agency: National Cancer Institute Division of Cancer Prevention

Name and address of funding agency's Grant's Officer:

Umar Asad, DVM, PhD

National Cancer Institute

Gastrointestinal & Other Cancers Research Group

Division of Cancer Prevention National Cancer Institute

9609 Medical Center Drive

MSC 9782

Room: 5E226

Bethesda, MD 20892-9782

umara@mail.nih.gov

Performance Period: 07/2022-06/2027

Level of funding:

Brief description of project's goals: The overarching goal of this project is to reduce the burden of hepatocellular carcinoma (HCC)-related mortality through better understanding of contemporary risk factors and protective factors of HCC related to metabolic (dysfunction) fatty liver disease (MAFLD).

% Overlap: None

Title: 1U01CA271887-01 Clinical Validation Center for Hepatocellular Carcinoma

Role on project: MPI

AIMS: 1) Facilitate efficient validation of blood and imaging biomarkers for risk stratification and early detection of HCC by expanding contemporary blood and radiology biorepositories of patients with and without HCC; 2a) Evaluate the performance of a risk stratification model to stratify patients with indeterminate liver nodules (ILNs) into low- and high-risk of developing HCC; 2b) Evaluate the performance of a serum biomarker panel, GALAD (including AFP, AFP-L3, and DCP) for early HCC detection in patients with indeterminate liver nodules (ILNs)

Time Commitment (Level of Effort): 1.2 calendar months

Supporting Agency: National Cancer Institute

Name and address of funding agency's Grant's Officer:

Sharmistha Ghosh-Janjigian, PhD

Program Director, Cancer Biomarkers Research Group

Room: 5E134

Division of Cancer Prevention

National Cancer Institute

9609 Medical Center Drive

Bethesda, MD 20892

Email: ghoshjanjigias@mail.nih.gov

Performance Period: 08/2022 – 07/2027

Level of funding:

Brief description of project's goals: The proposed project will leverage existing infrastructure across five health systems to create two novel resources not offered by the current sample sets including (1) a biorepository with both blood and imaging data from patients, with and without HCC, representing contemporary etiologies of liver disease for Phase I-II biomarker studies and (2) a prospective cohort of patients with indeterminate liver nodules to evaluate HCC risk stratification and early detection biomarkers to conduct Phase III biomarker studies using a prospective- specimen-collection, retrospective-blinded-evaluation (PRoBE) design. Overall, the CVC-HCC will lead to significant advances in phase I-III validation of novel biomarkers for HCC risk stratification and early detection, areas of need that will facilitate development of well-designed phase IV clinical utility trials with high potential for a long-lasting impact on liver cancer mortality.

% Overlap: None

PENDING

Title: 1 I01HX003541-01A1 Integrated, Veteran-Centered Care for Advanced Liver Disease (I-VCALD)

Role on project: MPI

AIMS: 1) Conduct a formative assessment of I-VCALD implementation for Veterans with advanced liver disease; 2) Evaluate the effectiveness of I-VCALD in a randomized controlled study at four VA centers; 3) Conduct a summative assessment of implementation outcomes of I-VCALD.

Time Commitment (Level of Effort): 3.0 calendar months

Supporting Agency: Department of Veterans Affairs Health Services Research & Development (HSR&D)

Name and address of funding agency's Grant's Officer:

Cathie Plouzek, PhD, PMP

Health Services Research and Development (10P9H)

Office of Research and Development, VA Central Office

Department of Veterans Affairs

810 Vermont Avenue NW

Washington, DC 20420

E-mail: cathie.plouzek@va.gov

Performance Period: 01/2023 – 12/2026 (JIT)

Level of funding:

Brief description of project's goals: The proposed project employs a whole person, Veteran-centered approach that identifies Veterans with advanced liver disease using a population-based health management system, and integrates curative and early supportive care using a virtual outreach nurse care counselor based at a liver transplant center to (1) discuss patient's understanding of illness severity and prognosis, (2) identify priorities and care preferences and (3) align curative and supportive care options to achieve patient priorities. %

Overlap: None

OVERLAP

There is no overlap between current projects and this application.

The study supported by the NIH/NCI grant (1 R01 CA256977-01; MPI: Kanwal; Singal) will conduct a comprehensive evaluation of multilevel factors hypothesized to play important roles in causing racial/ethnic and socioeconomic disparities in three key measures of cirrhosis prognosis: a) hepatic decompensation, b) liver-related hospitalization, and c) overall survival. The study supported by this grant is complementary but non overlapping with the study supported by the CPRIT grant (RP200633, PI: Kanwal), which focuses on disparities in only liver cancer. Although liver cancer is included in the larger composite outcome for Aim 1 of the R01, the scientific overlap is minimal because liver cancer is relatively rare compared to the other disparate complications of cirrhosis (progression to ascites, hepatic encephalopathy, gastrointestinal bleeding, hospitalizations) that are the main focus on the R01. Aims 2 and 3 of both grants are distinct with no overlap.

If the pending projects receive funding, Dr. Kanwal will adjust her effort on other projects after consultation with and approval from each affected funding agency program officer.

PREVIOUS, CURRENT, AND PENDING SUPPORT (PCPS)

KRAMER, JENNIFER R., MPH, PhD

Title: VA IIR 16-025 Less is More: Improving Antimicrobial Stewardship for Asymptomatic Bacteriuria

Role on project: Co-Investigator

AIMS: 1) Conduct formative assessments of context, barriers and facilitators at each of the four VA medical sites to inform intervention implementation; 2) Evaluate implementation of a scalable version of the Kicking CAUTI intervention in four geographically distinct VA medical centers, including acute and long-term care settings, with four contemporaneous controls; 3) Assess the financial implications of the intervention through a budget impact analysis

Time Commitment (Level of Effort): 0.6 calendar months

Supporting Agency: VA HSR&D

Name and address of funding agency's Grant Officer:

Cathie Plouzek, PhD, PMP

Health Services Research and Development (10P9H)

Office of Research and Development, VA Central Office

Department of Veterans Affairs

810 Vermont Avenue NW

Washington, DC 20420

E-mail: cathie.plouzek@va.gov

Performance Period: 02/2018-09/2021

Level of funding:

Brief description of project's goals: The main goal of this project is to implement the Kicking UTI intervention across four VA sites nationally. Kicking UTI is an intervention to improve management of Asymptomatic Bacteriuria in Veterans in hospitals and long-term care, to protect Veterans from the harms of unnecessary antibiotic use. It was designed and validated in a previous study.

% Overlap: None

Title: HSR&D Project # IIR 16-075 (Application # 1 I01 HX002204-01A2) Patient Centered Care for Individuals with Advanced Liver Disease

Role on project: Co-Investigator

AIMS: 1) To develop risk stratification models of advanced liver disease (AdvLD) prognosis; 2) To describe patients' experiences and goals of AdvLD care; 3) To identify clinicians' perceptions of opportunities and barriers to patient-centered AdvLD care.

Time Commitment (Level of Effort): 0.6 calendar months

Supporting Agency: VA HSR&D

Name and address of funding agency's Grant Officer:

Cathie Plouzek, PhD, PMP

Health Services Research and Development (10P9H)

Office of Research and Development, VA Central Office

Department of Veterans Affairs

810 Vermont Avenue NW

Washington, DC 20420

E-mail: cathie.plouzek@va.gov

Performance Period: 05/2018-04/2021 (NCE 05/2021-04/2022)

Level of funding;

Brief description of project's goals: The main goal of the project is to develop a patient-centered care model for advanced liver disease, including risk-prediction models and clinician-patient collaborative treatment planning guides that focus on addressing patient unmet needs and expectations about illness course and care preferences for curative, supportive, and palliative care. The study findings will have direct impacts on current advanced liver disease care, as well as provide evidence for developing innovative care models for other serious chronic illnesses.

% Overlap: None

Title: 5R01CA212008-02 Harms of Hepatocellular Carcinoma Screening in Patients with Cirrhosis Role on project: Co-Investigator

AIMS: 1) Assess the effect of HCC screening on a) physical harms due to follow-up tests, b) financial harms, and c) overdiagnosis in patients with severe liver dysfunction or comorbid illness, through electronic medical record data, manual chart review, and validated survey measures; 2) Assess the effect of HCC screening on screening-related psychosocial harms, e.g. cancer-specific worry, situational anxiety, mood disturbances, and decisional regret, through longitudinal validated measures and qualitative interviews; 3) Create and disseminate a balance sheet of benefits and harms to inform patients, nurses, providers, healthcare organizations, payers, and policymakers about the value of HCC screening in patients with cirrhosis.

Time Commitment (Level of Effort): 0.6 calendar months

Supporting Agency: National Cancer Institute

Name and address of funding agency's Grant Officer:

Crystal Wolfrey

Chief Grants Management Officer

National Cancer Institute

Office of Grants Administration

9609 Medical Center Drive

West Tower, 2nd floor

Rockville MD 20850

wolfreyc@mail.nih.gov,

Performance Period: 08/2017-07/2022

Level of funding;

Brief description of project's goals: The purpose of this study is to investigate the harms that may be associated with screening for HCC in patients with cirrhosis recruited from 4 medical centers in Texas.

% Overlap: None

CURRENT

Title: VA HSR&D IIR 19-365 Enhancing the Efficiency of Data Collection for Surgical Quality Improvement (new)

Role on project: Co-Investigator

AIMS: Specific Aim 1: Evaluate whether analyzing all VASQIP eligible non-cardiac surgical cases, relative to current systematic case sampling, improves negative predictive value (i.e.: decreases false negative rates) for identifying VA hospitals with outlier performance; Specific Aim 2: Compare the use of hybrid CDW and clinical registry data, relative to clinical registry alone, for evaluating risk-adjusted surgical performance at VA hospitals; Specific Aim 3: *Conduct semi-structured interviews with SQNs to understand and inform how more efficient VASQIP data collection could affect and potentially enhance local QI efforts.*

Time Commitment (Level of Effort): 1.2 calendar months

Supporting Agency: Department of Veterans Affairs Health Service Research and Development

Name and address of funding agency's Grant's Officer:

Cathie Plouzek, PhD, PMP

Health Services Research and Development (14RD)

Office of Research and Development, VA Central Office

Department of Veterans Affairs

810 Vermont Avenue NW

Washington, DC 20420

E-mail: cathie.plouzek@va.gov

Performance Period: 05/01/2021-04/30/2025

Level of funding:

Brief description of project's goals: This mixed-methods proposal will evaluate the reliability of VASQIP's current case sampling strategy for identifying outlier VA hospitals, explore the use of hybrid data as a means of enhancing data collection efficiency, and will identify how more efficient data collection could enhance local QI through semi-structured interviews with Surgical Quality Nurses.

% Overlap: None

Title: 1P01CA263025-01A1 Prevention of Hepatocellular Carcinoma Related to Metabolic Syndrome, Project 2 (new)

Role on project: co-I

AIMS: 1) To examine the chemopreventive effects for each of metformin, statins, and glitazones in reducing the risk of incident HCC among individuals with MAFLD; 2) To measure potential harms of metformin, statins and glitazones in individuals with MAFLD; 3) To examine the modifying effects of genetic markers on chemopreventive benefits of metformin and statins in a high-risk group of patients with MAFLD cirrhosis. **Time**

Commitment (Level of Effort): 1.2 calendar months

Supporting Agency: National Cancer Institute Division of Cancer Prevention

Name and address of funding agency's Grant's Officer:

Umar Asad, DVM, PhD

National Cancer Institute

Gastrointestinal & Other Cancers Research Group

Division of Cancer Prevention National Cancer Institute

9609 Medical Center Drive

MSC 9782

Room: 5E226

Bethesda, MD 20892-9782

umara@mail.nih.gov

Fax: (240)276-7848

Performance Period: 07/2022-06/2027

Level of funding:

Brief description of project's goals: The overarching goal of this project is to reduce the burden of hepatocellular carcinoma (HCC)-related mortality through better understanding of contemporary risk factors and protective factors of HCC related to metabolic (dysfunction) fatty liver disease (MAFLD).

% Overlap: None

Title: 1 U01 CA230997-01 Risk Stratification for and Early Detection of Liver Cancer (new)

Role on project: co-I

AIMS: 1) Develop and test novel personalized risk stratification indices for predicting future HCC development in cirrhosis from diverse etiologies; 2) Develop and evaluate an algorithm combining existing HCC blood based biomarkers (AFP, AFPL3, DCP), their longitudinal changes and host features (e.g., cirrhosis etiology) to improve early HCC detection; 3) Evaluate novel plasma-based methylation markers for cell-free DNA (MDMs) as an independent surveillance biomarker for early HCC detection. Using the PProBE design, we will test 12 individuals MDMs identified in Phase 2 study.

Time Commitment (Level of Effort): 0.48 calendar months

Supporting Agency: NIH Consortium on Translational Research in Early Detection of Liver Cancer: Translational Research Centers (U01)

Name and address of funding agency's Grant's Officer:

Viviana Knowles

National Cancer Institute

Office of Grants Administration

9609 Medical Center Drive

West Tower, 2nd floor

Rockville MD 20850

viviana.knowles@nih.gov

Performance Period: 09/2018-08/2023

Level of funding:

Brief description of project's goals: The overarching goal of our Translational Research Center (TRC) is to reduce the mortality of hepatocellular cancer (HCC) by developing personalized indices that combine novel and existing biomarkers with clinical, behavioral and genetic data to improve clinical risk stratification and increase early detection of HCC.

% Overlap: None

Title: 1R01CA260689-01 (PQ3) Addressing Cancer Treatment Disparities for Persons with HIV

Role on project: Co-Investigator

Aims: Aim 1: To evaluate differences in the timing of cancer treatment initiation between PWH and matched uninfected patients, and risk factors for delayed treatment in PWH. Aim 2: To evaluate disparities in short-term SAEs and cancer treatment.

Time Commitment (Level of Effort): 1.4 calendar months

Supporting Agency: NIH/NCI

Name and address of funding agency's Grant Officer:

Geraldina Dominguez

National Cancer Institute

National Institutes of Health

31 Center Drive, Room 3A33

Bethesda, MD, USA 20852-2440

Email: domingug@mail.nih.gov

Performance Period: 06/15/2021 – 05/31/2026

Level of Funding: (subcontract total DC)

Brief Description of project's goals: This project will address critical knowledge gaps for the four most common NADCs in PWH treated with CRT/RT (anal, head and neck, lung, or prostate cancer).

% Overlap: None

Title: PR181562 Risk of hepatocellular cancer after virological cure with direct acting antiviral agents in individuals with hepatitis C (subject grant)

Role on project: Co-Investigator

AIMS: 1) To examine determinants of HCC in virologically cured patients and develop a risk prediction model for HCC in these patients; 2) To evaluate benefits versus harms of HCC surveillance in virologically cured patients; 3) To develop HCC Simulator, an online interactive tool for physicians and patients that provides the short- and long-term value of HCC surveillance in different risk groups.

Time Commitment (Level of Effort): 2 calendar months

Supporting Agency: Department of Defense Office of Congressionally Directed medical Research Programs (CDMRP)

Name and address of funding agency's Grant's Officer:

Claudio Ortiz, Ph.D.

Science Officer, Goldbelt Frontier

Congressionally Directed Medical Research Programs (CDMRP)

US Army Medical Research Materiel Command (USAMRMC)

1077 Patchel Street

Fort. Detrick, MD 21702-5024

Email: claudio.d.ortiz.ctr@mail.mil

Performance Period: 07/2019-06/2022

Level of funding:

Brief description of project's goals: The goal of this study is to examine the risk and determinants of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C (CHC) virologically cured with new direct acting antiviral agent (DAA) regimens and to identify cost-effective strategies for early detection of HCC in those patients.

% Overlap: None

Title: CPRIT RP200633 Reducing disparities in the risk of hepatocellular cancer

Role on project: co-Investigator

AIMS: 1) Examine the role of individual, inter-personal and community level factors in explaining racial/ethnic disparities in cirrhosis progression to HCC (prevention); 2) Examine the role of individual, inter-personal and community level factors in explaining racial/ethnic disparities in HCC tumor stage at diagnosis (early detection); 3) Identify specific targets for future interventions to reduce racial/ethnic HCC disparities.

Time Commitment (Level of Effort): 1.9 calendar months

Supporting Agency: Cancer Prevention & Research Institute of Texas (CPRIT)

Name and address of funding agency's Grant's Officer:

General CPRIT Contact Information:

Email: cprit@cpritis.state.tx.us

Cancer Prevention and Research Institute of Texas

1701 North Congress Avenue, Suite 6-127

Austin, TX 78701

Performance Period: 08/2020-08/2025

Level of funding:

Brief description of project's goals: The primary objective of this study is to identify in a large racial/ethnically and socioeconomically diverse cohort of patients with cirrhosis the multi-level factors that explain racial and ethnic disparities in HCC risk/incidence and tumor stage at diagnosis, as well as a set of potentially actionable (identifiable, preventable or treatable) determinants of HCC disparities in Texas.

% Overlap: None

Title: 1R01CA256977 Multi-level Evaluation of Racial/Ethnic and Socioeconomic Disparities in Liver Disease Outcomes

Role on project: co-Investigator

AIMS: 1) Examine the contribution of individual-, interpersonal-, and community-level factors to racial/ethnic and socioeconomic disparities in cirrhosis progression to hepatic decompensation, including HCC; 2) Identify

individual-, interpersonal-, and community-level determinants of racial/ethnic and socioeconomic disparities in liver-related hospitalization; 3) Characterize the contribution of individual-, interpersonal-, and community-level factors to racial/ethnic and socioeconomic disparities in overall survival of patients with cirrhosis.

Time Commitment (Level of Effort): 1.9 calendar months

Supporting Agency: National Institutes of Health

Name and address of funding agency's Grant's Officer:

Rina Das, PhD

National Institute on Minority Health and Health Disparities (NIMHD (<https://www.nimhd.nih.gov/>)) Email: dasr2@mail.nih.gov (<mailto:dasr2@mail.nih.gov>)

Performance Period: 03/2021-02/2026

Level of funding:

Brief description of project's goals: To conduct a comprehensive evaluation of multilevel factors hypothesized to play important roles in causing racial/ethnic and SES disparities in three key measures of cirrhosis prognosis: a) hepatic decompensation, including HCC, b) liver-related hospitalization, and c) overall survival.

% Overlap: None

PENDING

OVERLAP

None

PREVIOUS/ CURRENT/ PENDING SUPPORT

LI, LIANG

PREVIOUS

PREVIOUS

Title/Grant Number: Media-rich mobile dissemination of a dysphagia prevention program for head and neck cancer patients during radiation / PP150077

Effort: 0.24 Calendar Months, 2% Effort (all years of participation)

Supporting Agency: Cancer Prevention & Research Institute of Texas (CPRIT)

Grants Officer: Patricia Moore, 512-463-3190, cpnit@cpnit.state.tx.us

Performance Period: 6/1/2015-5/30/2020

Funding Amount:

Project Goals: To provide evidence-based speech pathology functional swallow evaluation. PID600053 (Completed 12/31/2019)

Specific Aims: 1) Pre- and post-treatment and targeted swallowing exercises to head and neck cancer patients during radiation.

2) To administer an effective adherence program via a mobile health technology application (GuideVue) to head and neck cancer patients during radiation.

3) To lay the groundwork for future dissemination of this prevention program.

Overlap: None

Title/Grant Number: The Texas Hepatocellular Carcinoma Consortium (THCCC) Core 2: (SCC) / RP150587

Effort: 0.6 Calendar Months, 5% Effort (all years of participation)

Supporting Agency: Subaward from Baylor College of Medicine pass through from CPRIT

Grants Officer: Patricia Moore, 512-463-3190, cpnit@cpnit.state.tx.us

Performance Period: 6/1/2015-5/31/2020

Funding Amount:	
Project Goals:	Provide critical statistical, data management, and multi-center study coordination and support for all projects in the consortium. PID600060
Specific Aims:	1) Use Texas VA datasets to assemble the largest NAFLD-to-HCC study to date (including over 45,000 NAFLD patients in Texas) to determine the number of patients to develop HCC and to identify factors that increase patients' risk for HCC. 2) Develop risk stratification algorithms based on demographic, clinical, molecular and epidemiological risk factors to identify cirrhosis patients who might benefit from prevention or intensive surveillance. 3) Identify pathways for chemoprevention related to the role of circadian rhythm and bile acids in AFLD, metabolic syndrome, and HCC. 4) Identify and validate novel blood markers (tests) for early HCC detection. 5) Comparative effectiveness randomized controlled trial of strategies to increase HCC surveillance.
Overlap:	None
Title/Grant Number:	Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer: Coordinating and Data Management Center (CSCPDP-CDCM)/ 5U01DK108328-05
Effort:	2.4 Calendar Months, 20% Effort (all years of participation)
Supporting Agency:	NIH/NIDDK
Grants Officer:	Aynur Unalp-Arida, aynur.unalp-arida@nih.gov
Performance Period:	9/28/2015-8/31/2020
Funding Amount:	
Project Goals:	Coordinate the research efforts and will manage and analyze the data for the Consortium under the direction of the Consortium Steering Committee (SC). PID3496
Specific Aims:	1) Provide coordination of the Consortium in order to enhance communication and collaboration among Consortium investigators and with the larger scientific communities. 2) provide scientific and statistical leadership for the Consortium in research strategy, study design approaches, and statistical and computational methods 3) coordinate Consortium collaborative studies.
Overlap:	None
Title/Grant Number:	Using game mechanics to improve among stem cell transplant/ 2R42CA168107-03
Effort:	0.6 Calendar Months, 5% Effort (all years of participation)
Supporting Agency:	Radiant Creative Group, LLC
Grants Officer:	Patricia A Weber; weberpa@mail.nih.gov
Performance Period:	12/1/2015-11/30/2018
Funding Amount:	
Project Goals:	To develop an innovative interactive online intervention that utilizes novel social game mechanics to promote improved self-management behaviors among patients who have undergone hematopoietic stem cell transplantation for treatment of leukemia and lymphoma. PID4024
Specific Aims:	To determine the impact of the intervention during the post-HSCT phase, and to evaluate changes and trends in the psychosocial and behavioral outcomes during the immediate post-HSCT recovery phase. The proposed study will advance

scientific knowledge on the impact of game mechanics and social networking on patient behavior, and will provide insights, evidence, and guidance on how to build practical online social intervention systems to support behavioral change in AYAs.

Overlap: None

Title/Grant Number: Visualizing T-cell Trafficking/ RP160013
 Effort: 0.12 Calendar Months, 1% Effort (all years of participation)
 Supporting Agency: Cancer Prevention & Research Institute of Texas (CPRIT)
 Grants Officer: Patricia Moore, cpvit@cpvit.state.tx.us
 Performance Period: 3/1/2016-2/28/2020
 Funding Amount:
 Project Goals: To develop SSTR2-based methods for marking T-cells in vitro and following T-cells in vivo. PID600080
 Specific Aims:
 1) Test the hypothesis that human somatostatin receptor type 2 (SSTR2)-based reporters can be created that are deficient in signaling and do not interfere with T-cell function in vitro.
 2) Test the hypothesis that non-invasive signaling deficient SSTR2-based reporter imaging can be used to localize T-cells in tumors and assess their expansion at the tumor site.
 3) Test the hypothesis that imaging T-cells expressing signaling deficient SSTR2-based reporters can be used to predict tumor response.
 4) Test the hypothesis that T-cells expressing signaling deficient SSTR2-based reporters persist against a subsequent tumor challenge. Thus, this proposal uses innovative methods to address significant unmet needs required to advance T-cell therapy.

Overlap: None

Title/Grant Number: Multi-Site Development & Evaluation of a Quantitative 3D Hyperpolarized C-13 MRI Clinical Prostate Cancer Exam / 5R01CA211150-05
 Effort: 0.24 Calendar Months, 2% Effort (all years of participation)
 Supporting Agency: NIH/NCI
 Grants Officer: Huiming Zhang, zhanghui@mail.nih.gov
 Performance Period: 03/1/2017-02/28/2023
 Funding Amount:
 Project Goals: Demonstrating new and improved imaging methods that enhance image quality, and consequently, improve sensitivity and specificity of minimally invasive metabolic imaging strategies. (Effort ended effective 9/1/22) PID5247
 Specific Aims:
 1) Establish a method for external validation of HP MRI measurements.
 2) Implement highly optimized preclinical dynamic HP MRS and MRI protocols and a robust constrained reconstruction algorithm for quantifying tumor metabolism using HP [1-13C]-pyruvate.
 3) Develop a data-driven HP MRI protocol and establish imaging characteristics in patients with head and neck cancers.

Overlap: None

Title/Grant Number: Socioeconomic status, stress, and smoking cessation / 5R01CA190329-06
 Effort: 0.12 Calendar Months, 1% Effort (all years of participation)
 Supporting Agency: NIH/NCI Subaward via University of Utah
 Grants Officer: Xinzhi Zhang, zhangx12@mail.nih.gov
 Performance Period: 7/1/2017-06/30/2022
 Funding Amount:
 Project Goals: To examine the influence of socioeconomic status and social history, contextual and environmental influences, bio-behavioral/psychosocial predispositions, and

Specific Aims: acute momentary precipitants on stress, smoking lapse, and abstinence PID5135 (under NCE)
 1) Delineates the key hypothesized pathway linking SES to stress to smoking lapse/abstinence.
 2) Delineates the key hypothesized links of environment/context and bio-behavioral/psychosocial predispositions with SES, smoking lapse/abstinence, and stress.
 3) Examines the dynamic relationships of acute precipitants and stress, and their influence on lapse/abstinence.

Overlap: None

Title/Grant Number: Using hunger training to enhance weight loss and modulate cancer-related biomarkers in women at high risk for breast cancer; a pilot study/ 1R21CA215415-01A1

Effort: 0.12 Calendar Months, 1% Effort (all years of participation)

Supporting Agency: NIH/NCI

Grants Officer: Agurs-Collins, Tanya, collinsta@mail.nih.gov

Performance Period: 8/11/2017-7/31/2019

Funding Amount:

Project Goals: To pilot test the synergistic effect of adding Hunger Training to a highly-disseminated, evidence-based lifestyle intervention. PID6143 (Effort completed as of 5/31/2019)

Specific Aims: 1) Determine the feasibility of adding Hunger Training to the DPP using the following criteria: accrual rates >50%, attrition rates <20% and, in the DPP-plus-HT group, training protocol adherence rates >75%.
 2) Estimate the magnitude of effect sizes and variation in outcome variables for the DPP-only and DPPplus-HT interventions on changes in weight; in metabolic and breast cancer risk biomarkers (e.g., fasting insulin and BG levels, levels of glycosylated hemoglobin, insulin resistance, adiponectin, interleukin-6, and Creactive protein); and in proposed behavioral mediators (e.g., reduction in total energy intake, overall eating frequency, percent of eating events occurring at or below the average fasting blood BG level).

Overlap: None

Title/Grant Number: Using hunger training to enhance weight loss and modulate cancer-related biomarkers in women at high risk for breast cancer; a pilot study/ 1R21CA215415-01A1

Effort: 0.24 Calendar Months, 2% Effort (all years of participation)

Supporting Agency: NIH/NCI

Grants Officer: Agurs-Collins, Tanya, collinsta@mail.nih.gov

Performance Period: 8/11/2017-7/31/2019

Funding Amount:

Project Goals: To pilot test the synergistic effect of adding Hunger Training to a highly-disseminated, evidence-based lifestyle intervention (Diabetes Prevention Program; DPP) on weight loss outcomes and on metabolic and breast cancer risk biomarkers in a sample of obese postmenopausal women. PID6143. (Effort completed as of 6/1/2018; PI left institution.)

Specific Aims: 1) Determine the feasibility of adding Hunger Training to the DPP using the following criteria: accrual rates >50%, attrition rates <20% and, in the DPP-plus-HT group, training protocol adherence rates >75%.
 2) Estimate the magnitude of effect sizes and variation in outcome variables for the DPP-only and DPPplus-HT interventions on changes in weight; in metabolic and breast cancer risk biomarkers (e.g., fasting insulin and BG levels, levels of

glycosylated hemoglobin, insulin resistance, adiponectin, interleukin-6, and C-reactive protein); and in proposed behavioral mediators (e.g., reduction in total energy intake, overall eating frequency, percent of eating events occurring at or below the average fasting blood BG level).

Overlap:

None

Title/Grant Number: Eliminating tobacco-related disparities among African Americans/5R01MD010362-04
Effort: 1.32 Calendar Months, 11% Effort (all years of participation)
Supporting Agency: NIH/NHMD Subaward via Utah University
Grants Officer: Xinzhi Zhang, zhangx12@mail.nih.gov
Performance Period: 8/28/2017-1/31/2021
Funding Amount:
Project Goals:

To examine the influence of demographics and social history, bio-behavioral and psychosocial predispositions, contextual and environmental factors, and acute individual and contextual precipitants on smoking lapse and abstinence. PID5129 (Effort complete as of 1/31/2019)

Specific Aims: 1) Influence of demographics and social history, bio-behavioral/psychosocial predispositions, contextual and environmental influences, and acute precipitants on smoking lapses among AA smokers. 2) Influence of demographics and social history, bio-behavioral/psychosocial predispositions, contextual and environmental influences, and acute precipitants on early and long-term abstinence from smoking among AA smoker.

Overlap:

None

Title/Grant Number: Affective science and smoking cessation: Real time real world assessment/1R01CA224537-01
Effort: 0.48 Calendar Months, 4% Effort (all years of participation)
Supporting Agency: NIH via subaward from University of Utah
Grants Officer: Rebecca Ferrer, ferrerra@mail.nih.gov
Performance Period: 01/1/2018-12/31/2022
Funding Amount:
Project Goals:

To create a more detailed and comprehensive conceptual model of the role of distinct emotions in self-regulation. PID6397 (Effort complete as of 12/31/2018)

Specific Aims: 1) Models the impact of distinct emotions on SRC and smoking lapse, both in the moment and as trajectories over time. Aim 1 will also examine how the impact of specific emotions may differ based on the levels of other emotions (e.g., "blended" emotional states). 2) Investigates whether the associations of affective experience with SRC and lapse are modified by contextual factors.

Overlap:

None

Title/Grant Number: Multimodal Imaging and Therapy of Ovarian Cancer / 1R01CA255753-01A1
Effort: 0.6 Calendar Months, 5% Effort (all years of participation)
Supporting Agency: NIH/NCI
Grants Officer: Christopher Hatch, Ch29v@nih.gov
Performance Period: 7/1/2021-6/30/2026
Funding Amount:
Project Goals:

To create a new paradigm for approaching ovarian cancer that enables presurgical planning, surgical resection, and tumor photodestruction after a single nanoparticle injection. FP00010097_Res1 (PI left institution prior to project starting, award to be transferred to new institution)

Specific Aims: 1) Test the hypothesis that ovarian tumor delivery can be augmented by targeting DM-Dual-Gd to proven targets or novel imaging target CDCP1.

- 2) Test the hypothesis that ovarian tumor detection can be improved using the NIR II window compared to the NIR I window.
- 3) Test the hypothesis that DM-Dual-Gd-based nanoparticles enable photodestruction of ovarian tumors.
- 4) Test the hypothesis that pre-surgical NIR imaging employing DM-Dual-Gd can improve survival of models of intraperitoneal ovarian cancer.

Overlap: None

Title/Grant Number: Comparative Effectiveness Research on Cancer in Texas (CERCIT) 2.0: Data Core / RP160674

Effort: 0.12 Calendar Months, 1% Effort (all years of participation)

Supporting Agency: Cancer Prevention & Research Institute of Texas Subaward via UTMB

Grants Officer: Patricia Moore, cpnit@cpnit.state.tx.us

Performance Period: 6/1/2016-8/30/2022

Funding Amount:

Project Goals: To create a statewide resource for outcomes and comparative effectiveness research in cancer for Texas. PID4721 (No Cost Extension)

Specific Aims:

- 1) Create Data Resource of linked cancer and claims data for Texas residents.
- 2) Use data resource to examine the entire trajectory of cancer care in Texas.
- 3) Train the next generation of cancer outcomes and comparative effectiveness investigators in Texas.
- 4) Disseminate Findings.

Overlap: None

CURRENT

Title/Grant Number: Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer: Coordinating and Data Management Center (CSCPDP-CDMC)/5U01DK108328-08

Effort: 2.4 Calendar Months, 20% Effort (all years of participation)

Supporting Agency: NIH/NIDDK

Grants Officer: Aynur Unalp-Arida, aynur.unalp-arida@nih.gov

Performance Period: 9/28/2015-6/30/2025

Funding Amount:

Project Goals: To provide network coordination and collaborative activities, will provide scientific leadership in study design, statistical support, and computational analyses, and will provide data management and protocol development and execution. PID11706

Specific Aims:

- 1) Support Operation and Coordination of CPDPC
- 2) Continue the Accrual and Follow up of Patients in CPDPC-approved Studies
- 3) Support the Infrastructure for Biomarker Development, Prevention Studies, and Therapeutic Trials
- 4) Design and Support New Studies as Selected by the Steering Committee.

Overlap: None

Title/Grant Number: Estimating the Cost Trajectories and Projecting the Cost of Cancer Care in the United States: Methodology and Application / 5R01CA225646-05

Effort: 2.28 Calendar Months, 19% Effort (all years of participation)

Supporting Agency: NIH/NCI

Grants Officer: Martinson Owusu, owusumo@mail.nih.gov

Performance Period: 7/5/2018-6/30/2023

Funding Amount:

Project Goals: To develop novel methodology and apply the methodology to estimate and project the future cost of cancer care in the US. PID6729

Specific Aims:

- 1) To develop new statistical methods to model the longitudinal incident costs of cancer patients.

- 2) To improve the net costing approach by developing innovative propensity score methods for the selection of non-cancer controls.
- 3) To project the cancer care costs in the United States for the next 10 years.
- 4) To facilitate the reproducibility and application of the methods developed from this project by developing and disseminating user-friendly software programs.

Overlap:

None

Title/Grant Number: Magnetic resonance Imaging as a Non-Invasive Method for Assessment of Pancreatic fibrosis (MINIMAP): a pilot study / 5R01DK116963-03

Effort: 0.12 Calendar Months, 1% Effort (all years of participation)

Supporting Agency: NIH/NIDDK via subaward from Indiana University

Grants Officer: Chelsie Bousum, cbousum@iu.edu

Performance Period: 09/20/2018-06/30/2023

Funding Amount:

Project Goals: To evaluate non-invasive methods to detect and quantify pancreatic fibrosis. PID7394. FP00004518 (Under no cost extension)

Specific Aims: 1). The objective of this protocol is to perform statistical analysis of de-identified data for the MINIMAP study.

Overlap:

None

Title/Grant Number: Dynamic Prediction of Renal Failure Using Longitudinal Prognostic Information among Patients with Chronic Kidney Disease and Kidney Transplant / 5R01DK118079-04

Effort: 2.28 Calendar Months, 19% Effort (all years of participation)

Supporting Agency: NIH/NIDDK

Grants Officer: Kevin C. Abbott, Kevin.abbott@nih.gov

Performance Period: 04/1/2019-03/31/2023

Funding Amount:

Project Goals: To develop novel DP methods for kidney/graft failure with adjustment for the competing risk by death, external validation and re-calibration, and creating software for routine use in clinical practice. PID7824

Specific Aims: 1) Develop novel statistical methodology for dynamic prediction;
2) Develop and externally validate dynamic kidney failure prediction models for (a) patients with CKD and (b) KTx recipients;
3) Develop and disseminate web-based dynamic prediction model software for clinical practice.

Overlap:

None

Title/Grant Number: Phase 1/2 Trial of Indomethacin in Chronic Pancreatitis (The PAIR Trial) / 5R21DK117212-03

Effort: 0.12 Calendar Months, 1% Effort (all years of participation)

Supporting Agency: NIH/NIDDK Subaward via May Clinic-Rochester

Grants Officer: Jose Serrano, serranoj@extra.niddk.nih.gov

Performance Period: 7/12/2019-3/31/2023

Funding Amount:

Project Goals: To investigate the pancreatic effects of IN in humans, and to correlate changes in a pancreatitis biomarker with changes in clinical symptoms of CP. PID11646 / FP00005110 (Under no cost extension)

Specific Aims: 1) the primary analysis will be a linear random intercept model that incorporates PJ PGE2 data from both baseline and day 28 from all randomized patients.
2) we will use multivariate analysis of variance model (MANOVA) with repeated measures. The multivariate outcomes include patient-related outcomes (BPI and

Overlap: PROMIS-10 scores) and PJ PGE2 concentrations between baseline and day 28.
None

Title/Grant Number: Risk Of Hepatocellular Cancer After Virological Cure With Direct Acting Antiviral Agents In Individuals With Hepatitis C/W81XWH-19-1-0689

Effort: 0.12 Calendar Months, 1% Effort (all years of participation)

Supporting Agency: DOD via subaward Baylor College of Medicine

Grants Officer: Baylor College of Medicine, subaward@bcm.edu

Performance Period: 9/1/2019-8/31/2023

Funding Amount:

Project Goals: To examine the determinants of hepatocellular carcinoma (HCC) in patients diagnosed with chronic hepatitis C (CHC) who have been virologically cured with the new direct acting antiviral (DAA) regimens. PID11158 / FP00008073

Specific Aims: 1) To examine determinants of HCC in virologically cured patients and develop a risk prediction model for HCC in these patients.
2) To evaluate benefits versus harms of HCC surveillance in virologically cured patients.
3) To develop an HCC Simulator, an online interactive tool for physicians and patients that provides the short- and long-term value of HCC surveillance in different risk groups.

Overlap: None

Title/Grant Number: A novel natural history study of medullary thyroid carcinoma: Incorporating the patient perspective to inform advanced disease management /5R01FD006650-04

Effort: 0.6 Calendar Months, 5% Effort (all years of participation)

Supporting Agency: NIH/FDA

Grants Officer: Daniel Lukash, daniel.lukash@fda.hhs.gov,

Performance Period: 9/1/2019-7/31/2023

Funding Amount:

Project Goals: To understand the pathway to progressive disease, integrating for the first time patients perspectives. PID8226

Specific Aims: 1) To fully characterize the disease longitudinally from both the clinical and patient perspectives to understand the significance of each in association with outcome.
2) To derive a treatment algorithm (decision aid) for utilization of MTC drug therapy in which the patient's unique set of values are considered.
3) To determine if current and novel biomarkers can be used to enhance decision making in the treatment of advanced disease.

Overlap: None

Title/Grant Number: Improving Risk Prediction for Li-Fraumeni Syndrome: A Practical Tool for Clinical Health Care Providers / RP200383

Effort: 0.12 Calendar Months, 1% Effort (all years of participation)

Supporting Agency: Cancer Prevention & Research Institute of Texas (CPRIT)

Grants Officer: Patricia Moore, cprit@cprit.state.tx.us

Performance Period: 8/31/2020- 8/30/2023

Funding Amount:

Project Goals: Improving the clinical management of individuals with a family history of early-onset cancers by developing a user friendly genetic counseling application to assess carrier probability and lifetime risk of developing cancers in individuals with TP53 mutations. PID11859

Specific Aims: 1) Validation of TP53 prediction (carrier status and cancer occurrence) using family data from MDACC Clinical Cancer Genetics Program.

2) LFSPRO dissemination into clinical genetic counseling practice.

Overlap: None

Title/Grant Number: Mechanism-based Approach to Pain in Chronic Pancreatitis (MAP-CP) / 5R21DK122293-02

Effort: 0.12 Calendar Months, 1% Effort (all years of participation)

Supporting Agency: NIH/NIDDK subaward via University Of Pittsburgh

Grants Officer: Jose Serrano, serranoj@extra.niddk.nih.gov

Performance Period: 9/14/2020-5/31/2023

Funding Amount:

Project Goals: To use data and serum collected by the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer as part of the PROCEED study to investigate the subtypes of pain in Chronic Pancreatitis and identify potential biomarkers. (Under NCE) FP00006539_Res1 PID12612

Specific Aims: This study is designed to test the hypothesis that patient-derived information can be used to identify pain phenotypes that inform management of chronic pancreatitis-related pain.

1) is to determine if distinct biomarker profiles can discriminate pain phenotypes. We will measure expression of selected targets in sera and compare across chronic pancreatitis patients stratified by pain characteristic (intensity, temporality, and interference) as well as pain mechanism (nociceptive versus neuropathic).

2) is designed to evaluate whether temporal changes in pain phenotype are associated with the natural course of disease and/or treatment such as opioid use.

Overlap: None

Title/Grant Number: Data Management and Analysis Core for Comparative Effectiveness Research on Cancer in Texas / RP210130

Effort: 1.2 Calendar Months, 10% Effort (all years of participation)

Supporting Agency: Cancer Prevention & Research Institute of Texas Subaward via UTMB

Grants Officer: Patty Moore, Email: research@cprit.texas.gov

Performance Period: 8/31/2021-8/30/2026

Funding Amount:

Project Goals: The Data Management and Analysis Core will become the hub for cancer comparative effectiveness research in Texas. PID13370

Specific Aims: 1) Support data management and analysis.

2) Expand our TCR linkage to nationally representative survey data.

3) Recruit and train new CER investigators from at least 8 Texas academic and research institutions with a large number of underrepresented investigators.

Overlap: None

PENDING

Title/Grant Number: A Pilot Clinical Trial of Paricalcitol for Chronic Pancreatitis /1R01DK132631-01

Effort: 0.6 Calendar Months, 5% Effort (all years of participation)

Supporting Agency: NIH/NIDDK subaward via Cedars-Sinai Medical Center

Grants Officer: Not available for this submission

Performance Period: 4/1/2022-3/31/2025

Funding Amount:

Project Goals: The objective of the study is to examine the feasibility of testing the effect of a potent vitamin D analogue, paricalcitol, on health-related quality of life (HRQoL) and

potentially delay disease progression in patients with Chronic Pancreatitis (CP).
FP00014083 (JIT Pending as of 9/14/22)

Specific Aims:

- 1) Conduct a randomized double-blind, placebo-controlled pilot trial of paricalcitol to evaluate the feasibility of performing subsequent efficacy focused trials. Feasibility will be met if the of patients who enroll and complete the 12-month study is $\geq 75\%$ of planned. There will be a 21-month recruitment period and a one-year treatment period.
- 2) Monitor health-related quality of life (HRQoL) measures; and imaging biomarkers and liquid biomarkers to identify measures/biomarkers that have the potential to measure responses to the treatment in subsequent efficacy focused trials.

Overlap: There is budgetary and scientific overlap under this application and the resubmission (1R01DK132631-01A1). If this submission is awarded, the resubmission will be withdrawn by the PD/PI. Alternatively, if the resubmission is funded, this submission will be withdrawn by the PD/PI.

Title/Grant Number: Coordinating and Data Management Center for Translational and Basic Science Research in Early Lesions/1U24CA274212-01

Effort: 1.8 Calendar Months, 15% Effort (all years of participation)

Supporting Agency: NIH/NCI

Grants Officer: Christos Patriotis, patriotisc@mail.nih.gov

Performance Period: 9/16/2022-8/31/2027

Funding Amount:

Project Goals: We propose to establish a Coordinating and Data Management Center (CDMC) for the Program on the Translational and Basic Science Research in Early Lesions (TBEL), which is being established to undertake various translational and basic science studies to provide fundamental knowledge on the mechanisms driving or restraining early cancers. **(Pending award setup as of 9/19/22 – 15% effort effective 10/1/22)** FP00015239

Specific Aims:

- 1) Statistical and computational support.
- 2) Data management, study protocol development and implementation.
- 3) Our team of experts include information technology specialists who have been supporting and developing innovative software tools for numerous basic and translation cancer studies, experienced research coordinators who have worked on both NIH- and industry-funded multicenter studies, and faculty statisticians and bioinformaticians who have led CDMC work for large NIH consortiums and are well-known experts in biostatistics and bioinformatics methodological research areas closely related to biomarker development, risk prediction, single cell analysis, image analysis, machine learning, and clinical trials.

Overlap: None

Title/Grant Number: Prevention of Hepatocellular Carcinoma Related to Metabolic Syndrome/1P01CA263025-01A1

Effort: 0.6 Calendar Months, 5% Effort (all years of participation)

Supporting Agency: NIH/NCI subaward via Baylor College of Medicine

Grants Officer: Yujing Liu, Ph.D. Deputy Director, Division of Receipt and Referral Center for Scientific Review National Institutes of Health, 6700B Rockledge Dr. Room 4518 Bethesda, MD 20892, E-Mail: liuyujin@mail.nih.gov

Performance Period: 7/1/2022-6/30/2027

Funding Amount:

Project Goals: To prevent HCC among people with MAFLD by investigating the role of chemoprevention, surveillance, and risk scores in 3 highly synergistic scientific

projects that are supported by 2 shared cores for data and samples collection and analysis. **(Pending receipt of subaward agreement from Baylor as of 9/19/22)**
FP00012063_Res1

Specific Aims: 1) To develop HCC risk stratification models based on phenotypic, metabolic, radiomic and genetic markers of metabolic dysfunction among patients with cirrhosis. We propose the analysis of data and biospecimens from the prospective THCCC cohort of >5000 patients with cirrhosis (and 350-400 incident HCC) to develop a suite of risk score algorithms) for predicting the risk of HCC among patients with cirrhosis.
2) To evaluate the chemopreventive effects and potential harms of metformin, statins or glitazones in reducing the risk of HCC in individuals with MAFLD. We propose a retrospective cohort study using national VA datasets of >580,000 patients with MAFLD. We will also examine the effect of genetic markers on the chemopreventive effects of these medications in patients with MAFLD cirrhosis in THCCC.
3) To examine comparative cost-effectiveness of prevention strategies in MAFLD.

Overlap: None

Title/Grant Number: A Pilot Clinical Trial of Paricalcitol for Chronic Pancreatitis/ 1R01DK132631-01A1
Effort: 0.6 Calendar Months, 5% Effort (all years of participation)
Supporting Agency: NIH/NIDDK subaward via Cedars-Sinai Medical Center
Grants Officer: Not available for this submission
Performance Period: 9/1/2022-8/31/2025
Funding Amount:
Project Goals: The objective of the study is to examine the feasibility of testing the effect of a potent vitamin D analogue, paricalcitol, on health-related quality of life (HRQoL) and potentially delay disease progression in patients with Chronic Pancreatitis (CP).
(Funding status pending as of 9/14/22) FP14083_Res1

Specific Aims: 1) Conduct a randomized double-blind, placebo-controlled pilot trial of paricalcitol to evaluate the feasibility of performing subsequent efficacy focused trials. Feasibility will be met if the of patients who enroll and complete the 12-month study is $\geq 75\%$ of planned. There will be a 21-month recruitment period and a one-year treatment period.
2) Monitor health-related quality of life (HRQoL) measures; and imaging biomarkers and liquid biomarkers to identify measures/biomarkers that have the potential to measure responses to the treatment in subsequent efficacy focused trials.

Overlap: There is budgetary and scientific overlap under this application and the original submission that is pending JIT review (1R01DK132631-01). If this submission is awarded, the original submission will be withdrawn by the PD/PI. Alternatively, if the original submission is funded, this submission will be withdrawn by the PD/PI.

Title/Grant Number: Assessment of Impact of blood pressure/phosphate-lowering Medication on CardioVascular Disease endpoints in Chronic Kidney Disease (AIM-CVD-CKD)/ #TBA

Effort: 1.8 Calendar Months, 15% Effort (all years of participation)

Supporting Agency: NIH/NCI subaward via Penn State University College of Medicine

Grants Officer: Not available for this submission

Performance Period: 4/1/2023-3/31/2028

Funding Amount:

Project Goals: Leveraging two epidemiological observational cohort studies, the Chronic Renal Insufficiency Cohort (CRIC) and the Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI), we propose to develop advanced causal inference techniques for exploring these treatment effects in CKD patients. FP00016518

Specific Aims: 1) Develop a novel propensity score process for causal inference to evaluate medication effects on time-to-event outcomes by incorporating time-dependent treatment administration and covariates.
2) Extend statistical methods proposed in Aim 1 for competing risk analysis to assess casual medication effects in the presence of death.
3) Conduct systematic evaluation of the proposed methods in Aims 1-2 through simulations and perform the analysis of the CRIC and ASSESS-AKI studies.

Overlap: None

Title/Grant Number: Biomarkers to stratify pain severity and type in pancreatic disease / #TBA
Effort: 1.2 Calendar Months, 10% Effort (all years of participation)
Supporting Agency: NIH/NIDDK subaward via Boston Children's Hospital
Grants Officer: Not available for this submission
Performance Period: 7/1/2023-6/30/2028
Funding Amount:
Project Goals: Based on the preliminary data from our labs and those of others, we hypothesize that CP has a unique objective set of blood- and/or urine-based biomarkers to stratify and grade CP-associated pain. In line with RFA-NS-22-050, we propose studies that will identify (UG3) and validate (UH3) biological biomarkers of CP pain. FP00017679

Specific Aims: 1) Map the plasma proteins, and cytokines/chemokines from a well-annotated CP cohort to identify pain biomarkers.
2) Map the urinary proteins, and cytokines/chemokines from a well-annotated CP cohort to identify pain biomarkers.
3) Validate all plasma biomarker candidates in an independent CP cohort.
4) Validate all urine biomarker candidates in an independent CP cohort.

Overlap: None

Title/Grant Number: Simvastatin Treatment to Improve Patient-Reported Outcomes in Patients with Chronic Pancreatitis/ #TBA
Effort: 0.6 Calendar Months, 5% Effort (all years of participation)
Supporting Agency: DOD subaward via Cedars-Sinai Medical Center
Grants Officer: Not available for this submission
Performance Period: 10/1/2023-9/30/2027
Funding Amount:
Project Goals: Our strategic goals within this topic area are to develop and test novel treatments and develop technologies for tracking progress of associated diseases and conditions. Our overarching goal is to develop treatments that improve symptoms and other outcomes of chronic pancreatitis (CP); and tests that can be used to monitor the effectiveness of treatments. FP17344
1 & 2, 10% year 3 & 4)

Specific Aims: 1) Determine feasibility of oral simvastatin (40mg) in patients with painful suspected or definite CP.
2) Ancillary measurements will be made in blood products collected before and during the trial to identify biomarkers associated with pain and HRQoL measures.
3. To extend the therapeutic benefit of simvastatin, we will test the ability of modulators of inflammatory and fibrosis pathways to augment the beneficial effect of simvastatin using pre-clinical models of CP.

Overlap: None

In-Kind: None

Foreign Collaboration: None

OTHER SUPPORT

JAGPREET CHHATWAL

CURRENT SUPPORT

R01 (Samir) 03/01/2019 – 02/28/2023 0.24 calendar months
National Institutes of Health total costs

Development of a Machine Learning Model to Integrate Clinical, Laboratory, Sonographic, and Elastographic Data for Noninvasive Liver Tissue Characterization in NAFLD

Goals: We have developed a set of general-purpose shear wave elastography (SWE) liver image analysis algorithms, termed SWE-Assist. We propose (1) to customize and refine SWE-Assist to create a new high-risk NASH-specific SWE image diagnosis toolkit, termed hrNASH-Det, and (2) to integrate hrNASH-Det with clinical, and laboratory data to create an accurate, non-invasive hrNASH diagnostic tool.

Role: Co-Investigator

Overlap with proposed project: None.

R01 (Deshmukh) 03/01/2019 – 02/28/2023 0.39 calendar months
National Institutes of Health total costs

Optimizing Age-based Anal Cancer Screening among People Living with HIV using Decision Analytic Modeling

Goals: The goal of the proposed research is to identify optimal (effective and cost-effective) age-specific anal cancer screening algorithms considering HSIL management using a Simulation Model of Anal Cancer.

Role: Co-Investigator

Overlap with proposed project: None.

UM1DA049394 (Williams) 04/01/2019 – 03/31/2023 3.53 calendar months
National Institutes of Health total costs

HEALing Communities Study: Developing and Testing an Integrated Approach to Address the Opioid Crisis (Data Coordinating Center)

Goals: We aim to evaluate the cost-effectiveness and budget impact of interventions that can reduce opioid-related deaths in HEALing Communities Study and other jurisdictions.

Role: Co-Investigator

Overlap with proposed project: None.

R37 CA231957 (Lubitz) 08/01/2019 – 07/31/2024 1.38 calendar months
National Institutes of Health total costs

Thyroid Nodule Treatment Optimization: A Personalized Approach

Goals: The objective of this proposed research is to harness a comprehensive computer model to simulate individuals with benign and malignant nodules in the U.S. population to identify optimal personalized treatment approaches.

Role: Co-Investigator

Overlap with proposed project: None.

(THIS AWARD)

W81XWH1910690 (Chhatwal) 09/01/2019 – 08/31/2023 2.98 calendar months
Department of Defense total costs

Risk of hepatocellular cancer after virologic cure with direct acting antiviral agents in individuals with hepatitis C

Goals: The overall goal of this study is to examine the determinants of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virologically cured with the new direct-acting antiviral regimens and to evaluate benefits versus harms of HCC surveillance in those patients.

Role: Co-Principal Investigator
Overlap with proposed project: None.

NSF 18-541 (Gopalappa) 01/01/2020 – 12/31/2023 0.81 calendar months
National Science Foundation total costs

Simulation and Decision-Analysis Algorithms for Integrated Modeling of Diseases: A healthy lives for all approach

Goals: The goal of the proposed research is to develop an integrated multi-disease modeling framework to inform public health strategy plans such as HealthPeople2020 that address social determinants, reduce disparities and aims for healthy lives for all.

Role: Principal Investigator

Overlap with proposed project: None.

Contract (Chhatwal) 03/01/2020 – 06/30/2023 (NCE) 0.84 calendar months
Task Force for Global Health total costs

Hepatitis C Elimination Simulator: An Interactive Global Analysis and Planning Tool for Hepatitis C Elimination

Goals: To help countries identify effective and affordable policies to diagnose and treat HCV, we are developing an interactive online tool, the Hep C Elimination Simulator that will provide country-level information on the HCV epidemic, model the impact of various diagnostic and treatment strategies on HCV disease burden, estimate the budget impact of different interventions, and track the treatment cascade and progress towards elimination.

Role: Principal Investigator

Overlap with proposed project: None.

(Loomba) 05/20/2020 – 04/30/2023 1.24 calendar months
University of California, San Diego total costs

Non-invasive screening of diabetics for advanced fibrosis due to NAFLD

Goals: This project will enable us to determine the circumstances under which NAFLD screening is efficient and cost-effective and identify optimal screening strategies for individuals based on age, sex, obesity, and other risk factors.

Role: Co-Investigator

Overlap with proposed project: None.

Completed Support

(Chhatwal) 01/01/2017 – 12/31/2018
Gilead Sciences, Inc.

Simulation of Patients Who Fail Treatment in the Era of DAAs in Europe

Goals: The overall goal is to estimate the burden of HCV in five European countries in the era of direct-acting antivirals (DAAs) who will fail to achieve sustained virologic response and will need some salvage treatment.

Role: Principal Investigator

Overlap with proposed project: None.

(Chhatwal) 5/10/2017 – 12/31/2018
Gilead Sciences, Inc.

Cost-effective strategies for elimination of Hepatitis C in Spain's prisons

Goals: The overall goal is to evaluate cost-effective strategies to scale-up HCV treatment in Spain's prisons that can lead to HCV elimination.

Role: Principal Investigator

Overlap with proposed project: None.

Merck (Chhatwal)

08/15/2017 – 06/30/2019

Merck Research Laboratories

Strategies for management of hepatitis C virus: A global optimization tool

Goals: We propose to develop a mathematical tool to inform optimal strategies for management of HCV in different countries that will lead to elimination of HCV by 2030.

Role: Principal Investigator

Overlap with proposed project: None.

AASLD Innovation Fund

01/01/2018 – 12/31/2019

American Association for the Study of Liver Diseases

NAFLD Simulator: An online tool for predicting long-term patient outcomes

Goals: We aim to develop an online, open-access tool, NAFLD Simulator, that will simulate the life course of patients with NAFLD and provide information on the long-term risks. This will serve as an educational tool in the clinical setting and aid in shared patient-physician decision-making.

Role: Principal Investigator

Overlap with proposed project: None.

Contractor Services Agreement

02/05/2018 – 03/31/2019

ChangeLab Solutions/CDC

Hepatitis C investment calculator: An online tool for state-level management of Hepatitis C burden

Goals: The objective of this project is to develop the Hepatitis C Investment Calculator, an interactive online tool that allows users to enter state-specific information (e.g. the price of DAAs, testing cost, treatment rates) and evaluate outcomes.

Role: Principal Investigator

Overlap with proposed project: None.

ENDED

(Chhatwal)

01/31/2018 – 12/31/2020

Foundation for Innovative New Diagnostics

total costs

Cost-effective analysis of Simplified diagnostic algorithms for Hepatitis C

Goals: The objective is to evaluate the long-term effectiveness and cost-effectiveness of different HCV diagnostic algorithms that FIND will implement as part of the demonstration research projects in India, Georgia, Myanmar, Vietnam, Cameroon, and Malaysia.

Role: Principal Investigator

Overlap with proposed project: None.

ENDED

(Chhatwal)

07/01/2020 – 02/28/2021

Johns Hopkins University

total costs

Informing State-level COVID-19 Testing and Contact Tracing using the COVID-19 Simulator

Goals: To address several time-sensitive policy decisions at the state and national level, we recently developed and launched an interactive COVID-19 policy simulation model. We propose to extend the COVID-19 Simulator to: (1) Estimate the underlying antibody prevalence of COVID-19 and active COVID-19 cases in each state, and (2) Evaluate minimum testing and contract tracing needed to mitigate the spread of COVID-19 at different phases of reopening in each state.

Role: Principal Investigator

Overlap with proposed project: None.

Research Scholar Grant (Chhatwal)

07/01/2017 – 06/30/2022 total costs

American Cancer Society

A personalized surveillance program for hepatocellular carcinoma

Goals: The goal of this proposal is to reduce the burden of hepatocellular carcinoma by identifying effective surveillance programs that improve early detection.

Role: Principal Investigator

Overlap with proposed project: None.

NSF 16-601 (Chhatwal)

08/15/2017 – 07/31/2022

National Science Foundation

total costs

Collaborative Research: Smart intervention strategies for Hepatitis C elimination

Goals: In this project, we will estimate the true disease burden of hepatitis C at the state and national level, identify effective control strategies using infectious disease modeling and optimal control theory, and develop decision support tools for practical use by stakeholders.

Role: Principal Investigator

Overlap with proposed project: None.

2035361 (Chhatwal)

07/01/2020 – 06/30/2022 (NCE) 0.00 calendar months

National Science Foundation

total costs

Mitigation and Suppression of Coronavirus Pandemic with Data-driven RAPID Decisions Using COVID-19 Simulator

Goals: To evaluate and identify effective mitigation strategies using COVID-19 Simulator at the county level in the US by considering testing rates in the absence and presence of COVID-19 pharmaceutical interventions.

Role: Principal Investigator

Overlap with proposed project: None.

(Chhatwal)

04/05/2021 – 03/31/2022

0.00 calendar months Johns

Hopkins University

total costs

Simulation modeling to end the COVID pandemic

Goals: (1) Estimate the timing of lifting of restrictions (by different phases) in each state considering different vaccine uptake rates. (2) Evaluate the effect of emerging SARS-CoV-2 variants on the timing of herd immunity in each state. (3) Improve general accessibility and user experience for COVID-19 Simulator by improving conducting user interface design research.

Role: Principal Investigator

Overlap with proposed project: None.

Pending Support

(Pandharipande)

09/01/2021 – 08/31/2026

0.60 calendar months

National Institutes of Health

total costs

Improving Treatment Selection in Advanced Ovarian Cancer

Goals: Our goal is to improve treatment selection and survival in women diagnosed with advanced ovarian cancer.

Role: Principal Investigator

Overlap with proposed project: None.

(El-Serag)

07/01/2022 – 06/30/2023

2.4 calendar months

National Institutes of Health

total costs

Prevention of Hepatocellular Carcinoma Related to Metabolic Syndrome

Goals: To examine the risk and determinants of hepatocellular cancer in patients with nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome.

Role: Project lead

Overlap with proposed project: None.

◦**What other organizations were involved as partners?**

MD Anderson Cancer Center (Houston, TX) provided the following types of support:

- In-kind support (partner makes software, computers, equipment, etc., available to project staff)
- Facilities (project staff use the partner's facilities for project activities)

University of Texas Health Science Center (Houston, TX) provided the following types of support:

- In-kind support (partner makes software, computers, equipment, etc., available to project staff)
- Facilities (project staff use the partner's facilities for project activities)

8.SPECIAL REPORTING REQUIREMENTS

◦**COLLABORATIVE AWARDS:**

The Initiating PI and the Collaborating/Partnering PI are submitting separate reports.

◦**QUAD CHARTS:**

Nothing to report.

9.APPENDICES:

Appendix I – Journal Publication – Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication

Appendix II – Abstracts Presented

ADDITIONAL NOTES:


Nothing to report.

MARKING OF PROPRIETARY INFORMATION:

Nothing to report.

Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication

Graphical abstract



Authors

Peter P. Mueller, Qiushi Chen, Turgay Ayer, ..., Naveed Z. Janjua, Fasiha Kanwal, Jagpreet Chhatwal

Correspondence

jagchhatwal@mgh.harvard.edu (J. Chhatwal).

Lay summary

Individuals who are cured of hepatitis C using oral antiviral drugs remain at risk of developing liver cancer. The value of lifelong screening for liver cancer in these individuals is not known. By simulating the life course of hepatitis C cured individuals, we found that ultrasound-based biannual screening for liver cancer is cost-effective up to age 70 in those with cirrhosis and up to age 60 in those with stable advanced fibrosis.

Highlights

- The value of lifelong surveillance for HCC in individuals after SVR is not known.
- Ultrasound-based bi-annual surveillance for HCC appears to be cost-effective up to age 75 in those with cirrhosis.
- This surveillance strategy was cost effective up to age 60 in those with stable advanced fibrosis.
- Compared with no surveillance, surveillance detected 86 additional HCCs in 'very early'/early stage per 1,000 patients with cirrhosis.



Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication

Peter P. Mueller^{1,†}, Qiushi Chen^{1,2,†}, Turgay Ayer³, Gizem S. Nemutlu¹, Ali Hajjar¹, Emily D. Bethea^{1,4}, Mary Linton B. Peters^{1,5}, Brian P. Lee⁶, Naveed Z. Janjua^{7,8}, Fasiha Kanwal^{9,10,‡}, Jagpreet Chhatwal^{1,4,*,‡}

¹Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; ²Harold and Inge Marcus Department of Industrial and Manufacturing Engineering, Pennsylvania State University, University Park, PA, USA; ³H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, GA, USA; ⁴Liver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, MA, USA; ⁵Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA; ⁶Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, CA, USA; ⁷British Columbia Centre for Disease Control, Vancouver, BC, Canada; ⁸School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada; ⁹Department of Medicine, Baylor College of Medicine, Houston, TX, USA; ¹⁰Houston Veterans Affairs Health Services Research and Development Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA

Background & Aims: Successful treatment of chronic hepatitis C with oral direct-acting antivirals (DAAs) leads to virological cure, however, the subsequent risk of hepatocellular carcinoma (HCC) persists. Our objective was to evaluate the cost-effectiveness of biannual surveillance for HCC in patients cured of hepatitis C and the optimal age to stop surveillance.

Methods: We developed a microsimulation model of the natural history of HCC in individuals with hepatitis C and advanced fibrosis or cirrhosis who achieved virological cure with oral DAAs. We used published data on HCC incidence, tumor progression, real-world HCC surveillance adherence, and costs and utilities of different health states. We compared biannual HCC surveillance using ultrasound and alpha-fetoprotein for varying durations of surveillance (from 5 years to lifetime) vs. no surveillance.

Results: In virologically cured patients with cirrhosis, the incremental cost-effectiveness ratio (ICER) of biannual surveillance remained below \$150,000 per additional quality-adjusted life year (QALY) (range: \$79,500–\$94,800) when surveillance was stopped at age 70, irrespective of the starting age (40–65). Compared with no surveillance, surveillance detected 130 additional HCCs in ‘very early’/early stage and yielded 51 additional QALYs per 1,000 patients with cirrhosis. In virologically cured patients with advanced fibrosis, the ICER of biannual surveillance remained below \$150,000/QALY (range: \$124,600–\$129,800) when surveillance was stopped at age 60, irrespective of the starting age (40–50). Compared with no surveillance, surveillance detected 24 additional HCCs in ‘very early’/early stage and yielded 12 additional QALYs per 1,000 patients with advanced fibrosis.

Conclusion: Biannual surveillance for HCC in patients cured of hepatitis C is cost-effective until the age of 70 for patients with cirrhosis, and until the age of 60 for patients with stable advanced fibrosis.

Lay summary: Individuals who are cured of hepatitis C using oral antiviral drugs remain at risk of developing liver cancer. The value of lifelong screening for liver cancer in these individuals is not known. By simulating the life course of hepatitis C cured individuals, we found that ultrasound-based biannual screening for liver cancer is cost-effective up to age 70 in those with cirrhosis and up to age 60 in those with stable advanced fibrosis. © 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Introduction

Chronic hepatitis C is the leading cause of hepatocellular carcinoma (HCC) in the United States. However, with the availability of new direct-acting antivirals (DAAs), 90–100% of patients with hepatitis C, even those who could not be treated with previously available interferon-based therapies, can now achieve a virological cure (defined as a sustained virological response or SVR).¹ Although successful treatment resulting in SVR represents a “cure” from the standpoint of persistent infection, the subsequent risk of HCC persists after treatment with DAAs and remains an important contributor to liver-related morbidity and mortality in the post-DAA era.^{2–4}

With the wide use of DAAs, the number of patients with virologically cured hepatitis C has rapidly increased from 0.5 million in 2012 to 1.5 million in 2020 in the United States.⁵ Similar trends are expected in other countries that have successfully treated a large number of patients with DAAs. Furthermore, the proportion of patients with advanced liver disease among this cohort has increased.⁶ As such, most patients with hepatitis C in clinical practice will be those who have been virologically cured with DAAs and yet have advanced liver disease, either fibrosis or cirrhosis.⁵ For instance, the number of individuals who could potentially benefit from HCC surveillance, i.e., those with advanced liver disease is projected to increase

Keywords: Liver cancer; screening; simulation modeling; health economics.
Received 26 March 2021; received in revised form 13 January 2022; accepted 28 January 2022; available online 12 February 2022

* Corresponding author. Address: MGH Institute for Technology Assessment, 101 Merrimac Street, Ste 1010, Boston, MA 02114, USA; Tel.: (617) 724-4445, fax: (617) 726-9414.

E-mail address: jagchhatwal@mgh.harvard.edu (J. Chhatwal).

† Co-first authors.

‡ Co-senior authors.

<https://doi.org/10.1016/j.jhep.2022.01.027>



ELSEVIER

from 106,000 in 2012 to 649,000 in 2030.⁶ For this growing population, routine HCC surveillance is critical to improve early cancer detection and improve survival outcomes.⁷

The optimal policy for routine HCC surveillance for patients with virologically cured hepatitis C remains unclear.^{8,9} Despite limited evidence on the cost-effectiveness of HCC surveillance for this patient group, the American Association for the Study of Liver Diseases (AASLD) recommends biannual ultrasound-based (with or without alpha-fetoprotein) surveillance for HCC in patients with cirrhosis who achieve virological cure with DAAs,¹ but does not recommend surveillance in patients with advanced fibrosis. In contrast, the European Association for the Study of the Liver (EASL) guidelines recommend biannual surveillance in patients with cirrhosis as well as bridging fibrosis.¹⁰ Furthermore, none of the guidelines specify any age at which to discontinue surveillance. Virologically cured hepatitis C patients have a higher life expectancy than patients with active hepatitis C,¹¹ and the value of lifetime HCC surveillance in this cohort is not known.

Our study's objective was to perform a comparative cost-effectiveness analysis to determine in which patients, and up to what age, the benefits of HCC surveillance outweigh the costs.

Materials and methods

Overview

We developed a microsimulation model (an individual-level state-transition model) that simulates the natural history of hepatitis C and HCC in patients who achieved SVR after hepatitis C treatment with DAAs. The model was used to evaluate the cost-effectiveness of biannual HCC surveillance by varying the starting age for surveillance from 40 to 70 (base age 50) and stopping age from 50 to lifetime. We incorporated data from recent studies on the risk of HCC in patients who achieved SVR with DAAs,^{2,12–17} real-world adherence to HCC surveillance,¹⁸ the accuracy of screening and diagnostic testing modalities,^{19–22} as well as HCC treatments including liver transplantation for selected patients.^{20,23–35} The model used a monthly time-step. Primary outcomes included life expectancy, quality-adjusted life years (QALYs), total costs, and

incremental cost-effectiveness ratio (ICER) of each of the simulated surveillance strategies.

Baseline population and natural history model

For the baseline population, we created a virtual cohort of 50-year-old patients (mean age of HCV treatment), all of whom had hepatitis C that had been cured by DAA treatment. We developed different patient profiles that varied age (range 40–70), sex, and the extent of liver disease (advanced fibrosis METAVIR score F3 or compensated cirrhosis METAVIR score F4). For each patient, we simulated their remaining lifespan *with* and *without* HCC surveillance. We tracked life expectancy, development of HCC, and stage of HCC at diagnosis for each virtual patient in this simulation model.

For each virtual patient, we simulated the clinical course of cured hepatitis C, including HCC development as well as the progression of liver disease (Fig. 1). In each month, patients could develop HCC at a “very early” stage that could later progress to “early” and “intermediate/advanced” stages. We defined HCC stage based on Barcelona Clinic Liver Cancer staging system and tumor size: “very early HCC” included patients with a tumor less than 2 cm in diameter, “early HCC” for those with a single tumor less than 5 cm or up to 3 tumors all less than 3 cm, and “intermediate/advanced HCC” for the remaining stages. We assumed that patients with F3 advanced fibrosis could not develop cirrhosis once in SVR.³⁶ In each month, patients with F4 cirrhosis could progress to decompensated cirrhosis. The rate of HCC development varied by the extent of liver disease, such that patients without HCC could develop more severe liver disease, thus increasing their risk of HCC (Table S1).

HCC incidence

We used recently published studies to estimate the incidence of HCC among hepatitis C patients who achieved SVR. For patients with compensated cirrhosis (F4 fibrosis stage), we used a weighted average of 6 studies that resulted in an incidence rate of 1.95 per 100 person-years (Supplement Section S1).^{2,12–16} For patients with advanced fibrosis (F3 stage), the HCC incidence




Fig. 1. Model schematic for the natural history of HCC in patients with hepatitis C who achieved an SVR on direct-acting antivirals. Patients could develop HCC and subsequently progress through different stages of HCC. Patients with cirrhosis could also progress to decompensated cirrhosis. DC, decompensated cirrhosis; F3, advanced fibrosis; F4, cirrhosis; HCC, hepatocellular carcinoma; SVR, sustained virologic response; TACE, transarterial chemoembolization.

rate was estimated from 2 studies that resulted in a weighted average of 0.58 per 100 person-years.^{16,17} In a sensitivity analysis, we allowed HCC risk to be higher and lower than the base case values.

HCC surveillance

For each virtual patient, we simulated 'no surveillance' vs. biannual HCC surveillance using both ultrasound and alpha-fetoprotein,^{19,22} as recommended by clinical guidelines. We simulated different HCC surveillance strategies by varying the duration of surveillance from 10 years to lifetime (in 5-year increments). For example, we simulated the following surveillance strategies for a 50-year-old patient: biannual HCC surveillance from age 50 to age 60, 65, 70, etc. If surveillance tests were normal, no further intervention was needed and the patient followed their natural history until the next surveillance test; if the surveillance tests were abnormal, the patient received a contrast-enhanced abdominal MRI to potentially confirm the diagnosis of HCC.^{19–21} After confirmation of HCC, patients began treatment for HCC. HCC could also be detected incidentally regardless of surveillance. We assumed that only a single MRI was required for diagnostic confirmation.^{37,38} We also accounted for imperfect adherence to biannual HCC surveillance as observed in practice (see [Supplementary Section S2](#)).³⁹

HCC treatment

We considered 4 HCC treatment options: ablation, resection, liver transplantation, transarterial chemoembolization, and other palliative treatments (including selective internal radiotherapy, external beam radiotherapy, and systemic chemotherapy). Selection of treatment depended on HCC stage as well as the liver disease severity at diagnosis ([Table S2](#)). Following the guidelines, we assumed that liver transplantation was available only for patients under the age of 75 with either decompensated cirrhosis or "early stage" HCC (i.e., within Milan criteria); and decompensated patients were not eligible for resection. Treatment distributions by both HCC stage and fibrosis stage were determined from published observational studies^{19,40} and expert opinion (see [Supplementary Section S3](#)).

Unlike resection, ablation, and transarterial chemoembolization, which were delivered soon after the diagnosis, patients selected for liver transplantation were assumed to be on the transplant waitlist for organ availability. During each month, patients could receive a liver transplant; the probability of transplant was based on the median wait times that were provided from Organ Procurement Transplant Network data, which were dependent on the HCC tumor stage and liver stage ([Table S1](#)). However, in each month, HCC could progress such that patients were no longer eligible for transplant. In addition, if patients reached the age of 75, they would no longer be eligible for liver transplant (see [Supplementary Section S4](#)).

Costs and quality-of-life

The cost of surveillance tests, HCC treatments, liver transplantation, and general liver disease management were extracted from published sources ([Table S1](#)). All costs were converted to 2020 US dollars using the Consumer Price Index. We also assigned quality-of-life utility weights to each health state and treatment. These utility weights were adjusted by age, liver

disease stage, and for the year of treatment (initial year vs. later years)^{23,32,41,42} ([Table S1](#)).

Model outcomes

For each simulated surveillance strategy and for each patient profile, we estimated the number of HCC cases detected by tumor stage, total QALYs, and costs. All future QALYs and costs were discounted at 3% per year. We then calculated the ICERs for each surveillance strategy. For each surveillance strategy and patient profile, we could determine if surveillance was cost-effective if the ICER remained below the willingness-to-pay threshold of \$150,000 per QALY.⁴³ To reduce first-order uncertainty, we simulated outcomes in 200 million virtual patients.

Subgroup and sensitivity analysis

We evaluated the cost-effectiveness of surveillance in several subgroups described by age, sex, diabetes status, and alcohol use.²

As a part of our sensitivity analyses, we varied the incidence of HCC following SVR across a range informed by several observational studies.^{2,12–17} We further evaluated the impact of uncertainty in each model input on outcomes by conducting *univariate* probabilistic sensitivity analysis on each model input. This was performed by randomly sampling values from each parameter's recommended statistical distribution one at a time ([Table S1](#)). We also conducted a *multivariate* probabilistic sensitivity analysis on *all* model parameters simultaneously by sampling 4,000 sets of parameter values from the recommended statistical distributions and evaluating each parameter set with a population size of 1.5 million. The *multivariate* probabilistic sensitivity analysis results were presented as cost-effectiveness acceptability curves.

Results

Base case cost-effectiveness results for HCC surveillance

[Table 1](#) shows the costs, QALYs, and ICERs of each HCC surveillance strategy. For 50-year-old patients with cirrhosis, the ICER of biannual HCC surveillance was \$93,587 per QALY when the stopping age of surveillance was 70 and \$223,364 per QALY when the stopping age increased to 75 ([Fig. 2A](#), [Table 1](#)), suggesting that HCC surveillance is cost-effective until the age 70 using a willingness-to-pay threshold of \$150,000. Compared with no surveillance, the cost-effective surveillance strategy – surveillance up to age 70 – provided QALY gains of 51 per 1,000 patients at an additional cost of \$2,694,400. Surveillance was cost-effective until the age of 70 regardless of starting age (from 40–65), with the ICERs remaining below the \$150,000-per-QALY threshold ([Fig. 2A](#)). Of note, for 65-year-old patients, the ICER of routine surveillance up to age 75 was \$147,563—below the \$150,000 threshold.

For 50-year-old patients with advanced fibrosis, the ICER of biannual HCC surveillance was \$98,800 per QALY when the stopping age of surveillance was 65 and \$129,781 per QALY when the stopping age increased to 70 ([Fig. 2B](#)), suggesting that HCC surveillance is cost-effective until age 65 using a willingness-to-pay threshold of \$150,000. However, the ICER of surveillance was cost-effective only up to age 60 when the starting age was 40, 45, and 50 ([Fig. 2A](#)). Compared with no surveillance, the cost-effective surveillance strategy –

Table 1. Base case cost-effectiveness results of biannual HCC surveillance in 50-year-old patients with virologically cured hepatitis C.

Surveillance stopping age	Compensated cirrhosis			Advanced fibrosis		
	QALYs	Costs (\$)	ICERs (\$/QALY)	QALYs	Costs (\$)	ICERs (\$/QALY)
No surveillance	11.718	38,534	—	14.384	3,568	—
60	11.755	40,243	46,000	14.396	5,081	129,781
65	11.765	40,819	60,625	14.399	5,649	160,348
70	11.769	41,228	93,587	14.401	6,096	275,280
75	11.770	41,526	223,364	14.401	6,444	772,400

HCC, hepatocellular carcinoma; ICERs, incremental cost-effectiveness ratios; QALYs, quality-adjusted life years.

surveillance up to age 60 – provided QALY gains of 12 per 1,000 patients at an additional cost of \$1,512,900.

For 50-year-old patients with cirrhosis in the “no surveillance” arm, for every 1,000 patients, 381 HCC cases were detected either as incidental findings or through symptoms – 9 were detected in very early stage, 93 in early stage, and 279 in intermediate/advanced stages (Fig. 3). In contrast, the cost-effective surveillance strategy (surveillance every 6 months until the age of 70) detected a total of 389 HCC cases – 82 were detected in very early stage, 150 in early stage, and 157 in intermediate/advanced stages. Therefore, this surveillance strategy detected 130 additional HCCs in ‘very early’/early stage. The surveillance strategy also identified 8 additional patients with HCC who would have died from competing mortality under no surveillance. Similar trends were observed in patients with advanced fibrosis. In 50-year-old patients with advanced fibrosis, 3 cases were detected in a very early stage, 37 in early stage, and 111 in intermediate/advanced stage in the “no surveillance” arm. In contrast, the cost-effective surveillance strategy (surveillance every 6 months until the age of 60) detected 17 cases in very early stage, 47 in early stage, and 88 in intermediate/advanced stage. Therefore, this surveillance strategy detected 24 additional HCCs in ‘very early’/early stage.

Effect of remaining life expectancy on surveillance

We found that biannual HCC surveillance would not be cost-effective in cirrhosis patients if their remaining life expectancy was under 16 years and not cost-effective in advanced fibrosis patients if their life expectancy was under 28 years. This finding did not change with the age of individuals.

Subgroup analysis

In 50-year-old patients with cirrhosis, biannual HCC surveillance was cost-effective until the age of 70 irrespective of alcohol use, male sex, diabetes status, and BMI (Table 2).

In patients with advanced fibrosis, biannual HCC surveillance was found to be cost-effective for an additional 10 years (until the age of 70) for men over the age of 55.

Sensitivity analysis

We evaluated a total of 59 parameters in the univariate probability sensitivity analysis. Tables S3 and S4 show the top 10 parameters, respectively, to which the model was most sensitive in virologically cured patients with compensated cirrhosis and advanced fibrosis, respectively. For individuals with compensated cirrhosis, the cost-effective surveillance strategy was most sensitive to the likelihood of incidental detection of HCC, the




Fig. 2. Incremental cost-effectiveness ratios of biannual HCC surveillance. (A) In patients with cirrhosis and (B) in patients with advanced fibrosis who achieved virological cure with direct-acting antivirals. In patients with cirrhosis, HCC surveillance is cost-effective up to approximately age 70 using a willingness-to-pay threshold of \$150,000 per quality-adjusted life year. In patients with advanced fibrosis, HCC surveillance is cost-effective up to age 60. HCC, hepatocellular carcinoma.




Fig. 3. Number of HCC cases according to surveillance approach. Number of HCC cases detected by tumor size in 50-year-old virologically cured patients under no surveillance vs. biannual surveillance until the age of 70 for patients with cirrhosis and until the age of 60 for patients with advanced fibrosis. CHC, chronic hepatitis C; HCC, hepatocellular carcinoma; SVR, sustained virologic response.

progression rate from early-stage HCC to intermediate/advanced stage HCC, and overall survival following palliative care. For advanced fibrosis individuals, the cost-effective surveillance strategy was most sensitive to the likelihood of incidental detection of HCC, MRI sensitivity for very early-stage HCC, and overall survival following liver transplant.

The results of the multivariate probabilistic sensitivity analysis are presented in the cost-effectiveness acceptability curve (Fig. 4),

which shows the likelihood of the cost-effectiveness of biannual HCC surveillance for different stopping ages when accounting for uncertainty in all model parameters. In patients with cirrhosis, surveillance for 25 years (*i.e.*, until the age 75) – in contrast to age 70 in the base case – was the most cost-effective option at the willingness-to-pay threshold of \$150,000. In patients with advanced fibrosis, surveillance for 20 years (*i.e.*, until age 70) – in contrast to age 60 in the base case – was the most cost-effective strategy at the willingness-to-pay threshold of \$150,000 per QALY. This suggests that the exact duration of HCC surveillance be longer than that reported in the base case results.

Table 2. Cost-effectiveness of HCC surveillance in selected subgroups of 50-year-old patients with virologically cured hepatitis C.

	HCC incidence per 100 person-years	Compensated cirrhosis	
		Cost-effective until age	ICER for 20 years of surveillance
Base case	1.95	70	93,600
Diabetes			
Yes	2.07	70	87,800
No	1.85	70	92,800
Alcohol use*			
Yes	2.15	70	86,500
No	1.66	70	98,900
Sex			
Male	2.01	70	89,500
Body mass index			
≥ 30 kg/m ²	2.48	70	79,100
< 30 kg/m ²	1.81	70	94,100
Male; age > 55; alcohol use: Yes	2.36	70	83,100
Male; age > 55; diabetes: Yes	2.09	70	89,700
		Advanced fibrosis	
		Cost-effective until age	ICER for 10 years of surveillance
Base case	0.58	60	129,800
Male age ≥ 55	1.36	70	89,300

HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio.

*Alcohol use was defined based on the AUDIT-C score ≥ 4 for men and ≥ 3 for women.

Discussion

Patients with hepatitis C that has been cured with oral DAAs remain at risk of developing HCC. With the wide use of DAAs, the number of patients virologically cured will rapidly increase in the near future.⁵ In this study, we evaluated the value of routine surveillance for HCC using a decision-analytic model that simulated the natural history of HCC in hepatitis C cured individuals. We found that biannual HCC surveillance is cost-effective in patients with compensated cirrhosis until the age of 70 and in patients with advanced fibrosis until the age of 60. These findings are important because virologically cured patients have a higher life expectancy than patients with active hepatitis C, and lifelong surveillance may not be warranted in this growing cohort.

Our study's conclusion supports AASLD and EASL's current HCC surveillance recommendations for HCC surveillance in patients with compensated cirrhosis who achieve virological cure with DAAs. For patients with stable advanced fibrosis – for whom the AASLD and EASL surveillance recommendations differ – our results align with the EASL's recommendation of the need for HCC surveillance. Of note, our study also identified an age cut-off at which to stop surveillance in both cohorts, which is not mentioned in either guideline.

An earlier study found that HCC surveillance is cost-effective in hepatitis C individuals who were successfully treated if they have cirrhosis.⁹ However, this study assumed patients would




Fig. 4. Cost-effectiveness acceptability curves. Cost-effectiveness acceptability curves showing the probability of cost-effectiveness for each surveillance strategy by different durations of hepatocellular carcinoma surveillance as defined by the stopping age in patients with (A) compensated cirrhosis and (B) advanced fibrosis. QALY, quality-adjusted life year.

undergo HCC surveillance for the duration of their lifetime. In contrast, we opted to test various ages to start and stop surveillance, as we know hepatitis C patients after achieving cure can live longer than those who do not achieve a SVR or those with other etiologies of liver disease. Our study's primary finding — that biannual surveillance is cost-effective until the age of 70 in individuals with compensated cirrhosis or until the age of 60 in individuals with advanced fibrosis — is important for the medical community as they work to define the optimal surveillance policy for HCC.

Surveillance may not be warranted in patients with HCC who are not eligible for curative treatments given factors such as age, comorbidity, liver disease severity, and access to transplant, among others. Therefore, we examined the benefits as well as the harms associated with surveillance in key subgroups, including those with advanced comorbidity. We found that HCC surveillance would not be deemed cost-effective if the remaining life expectancy is less than 16 years in patients with cirrhosis and less than 28 years in patients with advanced fibrosis. While our study found that HCC surveillance is cost-effective in virologically cured patients with advanced fibrosis until the age of 60, there could be subgroups of patients who have an elevated risk of HCC and could benefit from longer durations of surveillance. Therefore, future research is needed to identify risk factors and biomarkers in virologically cured patients with advanced fibrosis who could benefit from routine HCC surveillance.

Early diagnosis of HCC is critical to improved survival — patients with advanced HCC have a median survival of less than 1

year, while patients with early HCC can achieve 5-year survival rates near 70% with resection or transplantation.⁴⁴ Our analysis found that surveillance could produce a substantial stage shift, in which most HCC would be diagnosed at an early stage. Compared with 'no surveillance' arm, surveillance per 1,000 cirrhosis patients detected 130 additional HCCs in 'very early'/early stage and yielded 51 additional QALYs. Similarly, surveillance per 1,000 patients with advanced fibrosis detected 24 additional HCCs in 'very early'/early stage and yielded 12 additional QALYs.

Unlike other major cancers such as breast, prostate, and colorectal, surveillance for HCC remains underutilized in practice.⁴⁵ Several recent observational studies have shown the benefits of routine HCC surveillance.^{7,46} Ideally, a large randomized controlled trial could compare the long-term outcomes of surveillance with a no surveillance control arm;⁴⁷ however, this would be lengthy, and the use of a control arm would strain medical ethics.^{47,48} In this type of situation, decision-analytic models can simulate a virtual trial to generate comparative effectiveness data and inform screening policy. Simulation models are frequently used by policymakers to inform guidelines for cancer screening.^{49–52} Together with other recent reports,^{8,9} we believe our study provides helpful data to policymakers and professional societies in their evaluation of recommendations for HCC surveillance among high-risk patients.

This study has limitations. While our results remain robust for patients with compensated cirrhosis, limited data on HCC incidence in patients with advanced fibrosis warrant further

research before making strong conclusions on the duration of surveillance in these individuals. Second, we assumed that patients with fibrosis successfully treated with DAAs were no longer at risk of progression to cirrhosis, despite the clinical reality that these patients may show progression in cases of alcohol consumption or weight change. Future research is warranted to estimate HCC risk and cost-effectiveness of HCC surveillance in those subgroups. We believe future research should also evaluate the cost-effectiveness of HCC surveillance tailored to dynamic risk factors that change over time. Third, we only modeled primary HCC treatment, whereas most patients with HCC receive a sequence of treatments (such as a combination of ablation and transplantation). However, our estimates of life expectancy after HCC diagnosis and primary treatment included this treatment variability. We opted to simulate surveillance in 5-year increments rather than shorter time frames because such age intervals are easier to implement in practice. Lastly, aside from liver transplantation being restricted to patients under 75, no other age or comorbidity restrictions were assumed for other treatments.

In conclusion, we found that biannual surveillance for HCC in virologically cured patients with cirrhosis is cost-effective until age 70 and in virologically cured patients with stable advanced fibrosis until the age of 60. Future studies should identify subgroups of patients without cirrhosis who remain at risk of developing HCC and could benefit from a longer duration of HCC surveillance.

Abbreviations

AASLD, American Association for the Study of Liver Diseases; DAAs, direct-acting antivirals; EASL, European Association for the Study of the Liver; HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; SVR, sustained virological response.

Financial support

This study was supported by the American Cancer Society Research Scholar Grant RSG-17-022-01-CPPB (Chhatwal); the Office of the Assistant Secretary of Defense for Health Affairs under Award Numbers W81XWH-19-10689 (Kanwal) and W81XWH-19-10690 (Chhatwal); and the National Institutes of Health grants P30 DK 56338 (Kanwal), U01CA230997 (Kanwal), and K08 CA248473 (Peters). Dr. Kanwal is an investigator at the Veterans Administration Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413). None of the funding agencies have specific role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Conflict of interest

Dr. Peters received honoraria from Bayer, Exelixis and Agios, travel support from Halozyme, AstraZeneca and Exelixis, research support from Bayer, institutional research support from Taiho, AstraZeneca, BeiGene, Berg, Merck, all outside the submitted work. Dr. Ayer received consulting fee from Merck and served as principal scientist to Value Analytics Labs outside the submitted work. Dr. Chhatwal received consulting fee from Gilead, Merck, and Novo Nordisk, and served as principal scientist to Value Analytics Labs outside the submitted work.

Please refer to the accompanying ICMJE disclosure forms for further details.

Authors' contributions

Study concept and design: Mueller, Chen, Kanwal, Chhatwal. *Acquisition of data:* Mueller, Chen, Nemutlu, Hajjar, Peters, Lee, Janjua, Kanwal, Chhatwal. *Analysis and interpretation of data:* Mueller, Chen, Ayer, Nemutlu, Hajjar, Bethea, Peters, Lee, Janjua, Kanwal, Chhatwal. *Drafting of the manuscript:* Mueller, Chen, Kanwal, Chhatwal. *Critical revision of the manuscript for important intellectual content:* Mueller, Chen, Ayer, Nemutlu, Bethea, Peters, Lee, Janjua, Kanwal, Chhatwal. *Statistical analysis:* Mueller, Chen, Nemutlu, Hajjar, Lee. *Obtained funding:* Kanwal, Chhatwal. *Study supervision:* Chhatwal.

Data availability statement

All data generated from the simulation model are made available in the manuscript.

Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jhep.2022.01.027>.

References

Author names in bold designate shared co-first authorship

- [1] Ursoniu S, Sahebkar A, Serban MC, Antal D, Mikhailidis DP, Cicero A, et al. Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials. *Nutr Rev* 2017;75(5):361–373.
- [2] Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. *Gastroenterology* 2017;153(4):996–1005 e1.
- [3] Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. *Hepatology* 2020;71(1):44–55.
- [4] Maan R, Feld JJ. Risk for hepatocellular carcinoma after hepatitis C virus antiviral therapy with direct-acting antivirals: case closed? *Gastroenterology* 2017;153(4):890–892.
- [5] Chhatwal J, Wang X, Ayer T, Kabiri M, Chung RT, Hur C, et al. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. *Hepatology* 2016;64(5):1442–1450.
- [6] Chen Q, Ayer T, Adey MG, Wang X, Kanwal F, Chhatwal J. Assessment of incidence of and surveillance burden for hepatocellular carcinoma among patients with hepatitis C in the era of direct-acting antiviral agents. *JAMA Netw Open* 2020;3(11): e2021173-e.
- [7] Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. *PLoS Med* 2014;11(4):e1001624.
- [8] Singal AG, Ioannou GN. For whom is hepatocellular carcinoma surveillance after sustained virologic response cost-effective? *Clin Gastroenterol Hepatol : the official Clin Pract J of the American Gastroenterological Association* 2019;17(9):1732–1735.
- [9] Farhang Zangneh H, Wong WWL, Sander B, Bell CM, Mumtaz K, Kowgier M, et al. Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis. *Clin Gastroenterol Hepatol* 2019;17(9):1840–1849.e16.
- [10] EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. *J Hepatol* 2018;69(1):182–236.
- [11] Krajden M, Cook DA, Wong S, Yu A, Butt ZA, Rossi C, et al. What is killing people with hepatitis C virus infection? Analysis of a population-based cohort in Canada. *Int J Drug Pol* 2019;72:114–122.
- [12] Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. *Gastroenterology* 2018;155(2):411–421.e4.

- [13] Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. *The Lancet* 2019;393(10179):1453–1464.
- [14] Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, Lo Re V, et al. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study. *Hepatology* 2018;67(6):2244–2253.
- [15] Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, et al. Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs. *Gastroenterology* 2018;155(5):1436–1450.e6.
- [16] Shiha G, Mousa N, Soliman R, Nnh Mikhail N, Adel Elbasiony M, Khattab M. Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: a prospective study. *J of Viral Hepat* 2020;27(7):671–679.
- [17] Sánchez-Azofra M, Fernández I, García-Buey ML, Domínguez-Domínguez L, Fernández-Rodríguez CM, Mancebo A, et al. Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals. *Liver Int* 2021;41(12):2885–2891.
- [18] Zhao C, Jin M, Le RH, Le MH, Chen VL, Jin M, et al. Poor adherence to hepatocellular carcinoma surveillance: a systematic review and meta-analysis of a complex issue. *Liver Int* 2018;38(3):503–514.
- [19] Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. *Clin Gastroenterol Hepatol* 2008;6(12):1418–1424.
- [20] Goossens N, Singal AG, King LY, Andersson KL, Fuchs BC, Besa C, et al. Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis. *Clin Transl Gastroenterol* 2017;8(6):e101.
- [21] Ronot M, Vilgrain V. Hepatocellular carcinoma: diagnostic criteria by imaging techniques. *Best Pract Res Clin Gastroenterol* 2014;28(5):795–812.
- [22] Singal AG, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MAM, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. *Aliment Pharmacol Ther* 2009;30(1):37–47.
- [23] Cheung YB, Thumboo J, Gao F, Ng G, Pang G, Koo WH, et al. Mapping the English and Chinese versions of the functional assessment of cancer therapy-general to the EQ-5D utility index. *Value in health* 2009;12(2):371–376.
- [24] El-Fattah MA, Aboelmagd M, Elhamouly M. Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: a US population-based study. *United Eur Gastroenterol J* 2017;5(2):227–235.
- [25] Ikai I, Arai S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. *Cancer* 2004;101(4):796–802.
- [26] Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. *J of Hepatol* 2009;50(1):89–99.
- [27] Lencioni R, Cioni D, Crocetti L, Franchini C, Della Pina C, Lera J, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. *Radiology* 2005;234(3):961–967.
- [28] Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? *Hepatology* 2008;47(1):82–89.
- [29] Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. *Hepatology* 2003;37(2):429–442.
- [30] Llovet JM, Ducreux M. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J of Hepatol* 2012;56(4):908–943.
- [31] Sucandy I, Cheek S, Golas BJ, Tsung A, Geller DA, Marsh JW. Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors. *HPB (Oxford)* 2016;18(9):756–763.
- [32] Toro A, Pulvirenti E, Palermo F, Di Carlo I. Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment. *Surg Oncol* 2012;21(1):e23–e30.
- [33] Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 1999–2008. *American J of Transplant* 2010;10(4p2):961–972.
- [34] Yang W, Yan K, Goldberg SN, Ahmed M, Lee JC, Wu W, et al. Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment. *World J Gastroenterol* 2016;22(10):2993–3005.
- [35] Ratcliffe J, Longworth L, Young T, Bryan S, Burroughs A, Buxton M. Assessing health-related quality of life pre-and post-liver transplantation: a prospective multicenter study. *Liver Transplant* 2002;8(3):263–270.
- [36] Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. *J Hepatol* 2010;52(5):652–657.
- [37] Coon JT, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. *Br J of Cancer* 2008;98(7):1166–1175.
- [38] Trevisani F, De Notariis S, Rapaccini G, Farinati F, Benvenuto L, Zoli M, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). *Am J Gastroenterol* 2002;97(3):734–744.
- [39] Choi DT, Kum HC, Park S, Ohsfeldt RL, Shen Y, Parikh ND, et al. Hepatocellular carcinoma screening is associated with increased survival of patients with cirrhosis. *Clin Gastroenterol Hepatol* 2019;17(5):976–987.e4.
- [40] Mourad A, Deuffic-Burban S, Ganne-Carrie N, Renaut-Vantroys T, Rosa I, Bouvier AM, et al. Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach. *Hepatology* 2014;59(4):1471–1481.
- [41] Chhatwal J, Ferrante SA, Brass C, El Khoury AC, Burroughs M, Bacon B, et al. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. *Value in Health* 2013;16(6):973–986.
- [42] Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. *Med Decis Making* 2006;26(4):391–400.
- [43] Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness — the curious resilience of the \$50,000-per-QALY threshold. *New Engl J of Med* 2014;371(9):796–797.
- [44] Artinyan A, Mailey B, Sanchez-Luege N, Khalili J, Sun CL, Bhatia S, et al. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. *Cancer* 2010;116(5):1367–1377.
- [45] Singal AG, Tiro JA, Gupta S. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. *Clin Gastroenterol Hepatol* 2013;11(5):472–477.
- [46] Kansagara D, Papak J, Pasha AS, O'Neil M, Freeman M, Relevo R, et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. *Ann Intern Med* 2014;161(4):261–269.
- [47] Sherman M. Whither hepatocellular carcinoma screening? *Hepatology* 2012;56(6):2412–2414.
- [48] Chirovsky D, Lich KH, Barritt AS. Screening for hepatocellular carcinoma in chronic liver disease. *Ann Intern Med* 2015;162(3):238–239.
- [49] Kim JJ, Burger EA, Regan C, Sy S. Screening for cervical cancer in primary care: a decision analysis for the US preventive Services task force. *Jama* 2018;320(7):706–714.
- [50] van Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, Buist DSM, et al. Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. *Ann of Intern Med* 2012;156(9):609–617.
- [51] Knudsen AB, Zauber AG, Rutter CM, Naber SK, Doria-Rose VP, Pabiniak C, et al. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US preventive Services task force. *JAMA* 2016;315(23):2595–2609.
- [52] Section 5. Modeling. U.S. Preventive Services Task Force; July 2017. Retrieved from: <https://www.uspreventiveservicestaskforce.org/uspstf/procedure-manual/procedure-manual-section-5-modeling>. [Accessed 28 November 2020].

Kramer JR, Cao Y, Li L, Smith D, Chhatwal J, El-Serag HB, Kanwal F. Longitudinal associations between risk factors and subsequent risk of hepatocellular cancer in patients with hepatitis C virus infection and virological cure. 2021 AASLD The Liver Meeting, November 12-15th. Anaheim, CA.

Background: The risk of hepatocellular carcinoma (HCC) persists in patients with HCV after virological cure. We sought to determine if risk factors for HCC change as time from treatment elapses.

Methods: We utilized the Veterans Affairs data to examine a cohort of patients with HCV who achieved sustained viral response (SVR) from DAAs from 1/1/2014 to 12/31/2018, and followed until HCC diagnosis, death, or 12/31/2019. We utilized cause-specific Cox proportional hazard models constructed at 3 landmark times (baseline, 12 and 24 months after SVR) to examine the associations between demographic (age, race, sex, marital status), clinical (cirrhosis complications, duration of cirrhosis, FIB-4, albumin, sodium, bilirubin, creatinine, sodium, hemoglobin, obesity, hypertension and dyslipidemia), and behavioral factors (alcohol abuse, smoking) measured at these landmark times and the subsequent HCC risk, stratified by cirrhosis status.

Results: We identified 98,612 patients with virologic cure [38.5% Black, mean age 61 yrs]. Almost 32% had cirrhosis at time of SVR. Incident HCC developed in 2,298 patients. Among patients without cirrhosis, the annual incidence rates of HCC was 0.21% and 0.27% in year 1 and 2, respectively. The corresponding estimates were 1.6% and 1.9% in patients with cirrhosis. The association between risk factors and subsequent HCC changed over the landmark time and varied substantially with cirrhosis status. In patients **without cirrhosis**, metabolic traits (diabetes and hypertension) and increase in FIB-4 were strongly associated with HCC risk at all landmark times. In patients **with cirrhosis**, demographic factors (risk lower in females and blacks), viral factors (risk higher in HCV genotype 3), and cirrhosis related factors (risk higher with longer cirrhosis duration, presence of varices, higher bilirubin, and lower albumin) predicted HCC risk at 12 months. Change in serum albumin and FIB-4 scores between baseline and 12-month landmark times also predicted HCC risk. Race, HCV genotype, and bilirubin were no longer predictive of HCC risk at 24-month landmark time, whereas change in hemoglobin from baseline became associated with risk of HCC.

Conclusions: In a cohort of patients with virologically cured HCV infection, risk factors for HCC were different in patients with and without cirrhosis. In patients with cirrhosis, they were mostly disease severity related, whereas metabolic traits were important in patients without cirrhosis. These data could inform HCC surveillance decisions in patients with cured HCV.

Character count: 2564 (2500 max)

Table: Select risk factors from adjusted models for HCC at 12-months post SVR in patients with HCV infection stratified by cirrhosis status


Risk Factor	Patients without cirrhosis HR (95% CI)	Patients with cirrhosis HR (95% CI)
Change in FIB-4 (ref: stays low)		
Low at baseline (≤ 3.25) to high (> 3.25) at 12 mo.	2.36 (1.46-3.79)	1.45 (1.12-1.86)
High at baseline and stays high at 12 mo.	N/A	1.73 (1.50-2.00)
Diabetes	1.42 (1.16-1.75)	N/A
Hypertension	2.13 (1.47-3.07)	N/A
Cirrhosis duration > 60 months	N/A	1.71 (1.39-2.11)
Varices	N/A	1.58 (1.38-1.80)
Bilirubin	N/A	1.25 (1.11-1.41)
Change in albumin	N/A	0.79 (0.67-0.95)

Chhatwal J, Hajjar A, Mueller PP, Nemutlu G, Peters MLB, Kanwal F. Hepatocellular Carcinoma Incidence Threshold for Routine Surveillance is Much Lower in Hepatitis C Cirrhosis Individuals Who Achieve Virological Cure. 2021 AASLD The Liver Meeting, November 12-15th. Anaheim, CA. Also accepted for inclusion in the Best of The Liver Meeting's summary slide deck in the Health Services and Public Health Research category.

Background: The AASLD guidance recommends biannual surveillance for hepatocellular carcinoma (HCC) in hepatitis C virus (HCV) infected individuals with cirrhosis if HCC incidence is above 1.5 per 100 person-years (PY). However, the incidence threshold for surveillance in cirrhosis individuals who achieved virological cure with direct-acting antivirals is unknown. Our objective was to estimate the HCC incidence above which routine HCC surveillance is cost-effective in this growing population of individuals with virologically cured HCV.

Methods: We developed a microsimulation model of the natural history of HCC in individuals with HCV and cirrhosis who achieved virological cure with oral direct-acting antivirals (DAAs). We used published data on the natural history of HCV, competing risk post HCV cure, HCC tumor progression, real-world HCC surveillance adherence, contemporary HCC treatment options and associated costs, and utilities of different health states. We estimated the HCC incidence above which biannual HCC surveillance using ultrasound and alpha-fetoprotein would be deemed cost-effective using willingness-to-pay (WTP) thresholds of \$100,000 per quality-adjusted life year (QALY), as recommended by the 2nd US Panel on Cost-effectiveness.

Results: In 50-year-old virologically cured individuals with HCV cirrhosis, the incremental cost-effectiveness ratio (ICER) of biannual surveillance (up to age 75) vs. no surveillance was \$100,000-per-QALY at HCC incidence of 0.7 per 100-PY (Figure). At this HCC incidence, routine HCC surveillance vs no surveillance would result in additional 2,650 life years gained and 1400 QALYs per 100,000 persons undergoing surveillance. Using the WTP threshold of \$50,000-per-QALY (old willingness-to-pay), HCC surveillance could be cost effective at an annual HCC incidence of 2.0 per 100 PY.



Conclusion: Our study provides an important update on HCC incidence threshold above which routine HCC surveillance is cost-effective in individuals with HCV cirrhosis who achieved cure with DAAs. At the accepted WTP thresholds, HCC surveillance could be cost-effective if the annual incidence rate of HCC exceeds 0.7%, which is much lower than the previous 1.5% incidence used to guide HCC surveillance decisions.

Nemutlu G, Mueller PP, Qiushi Chen, Turgay Ayer, Naveed Janjua, Kanwal F, Chhatwal J. Liver Cancer Surveillance in the Era of New Hepatitis C Antiviral Treatments: A Value of Information Analysis. 2021 INFORMS Annual Meeting, October 27-27th 2021. Anaheim, CA.

The treatment landscape for chronic hepatitis C has changed with the use of direct-acting antivirals; 95-100% of individuals with hepatitis C can now be cured. However, the risk of liver cancer is not eliminated for individuals with advanced liver disease. The value of routine cancer surveillance in this population is widely debated; long-term data on liver cancer incidence is lacking. Our objective was to evaluate the value for future research on liver cancer surveillance in hepatitis C cured individuals using a validated microsimulation model. We estimated the cost-effectiveness of routine surveillance and performed a value of information analysis informed by the population-level expected value of perfect information to determine the value of future research. Our analysis showed that routine surveillance was cost-effective only in individuals with cirrhosis.